7or9 › Citations

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
<div class='caption-title'>Mutational landscape of the B.1.617 lineage</div>
<div class='caption-title'>Neutralization of B.1.617.1 and B.1.617.2 by mAbs</div>
Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai R, Zhou D, Mentzer AJ, Zhao Y, Duyvesteyn HME, López-Camacho C, Slon-Campos J, Walter TS, Skelly D, Johnson SA, Ritter TG, Mason C, Costa Clemens SA, Gomes Naveca F, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Temperton N, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert SC, Malik T, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Baillie V, Serafin N, Ditse Z, Da Silva K, Paterson NG, Williams MA, Hall DR, Madhi S, Nunes MC, Goulder P, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR
OpenAccess logo Cell 184 4220-4236.e13 (2021)
Related entries: 7ora, 7orb

Cited: 477 times
EuropePMC logo PMID: 34242578

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the United Kingdom. Here we study the ability of monoclonal antibodies and convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2, complement this with structural analyses of Fab/receptor binding domain (RBD) complexes, and map the antigenic space of current variants. Neutralization of both viruses is reduced compared with ancestral Wuhan-related strains, but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2, suggesting that individuals infected previously by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insights for immunization policy with future variant vaccines in non-immune populations.

Articles - 7or9 mentioned but not cited (5)

  1. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai R, Zhou D, Mentzer AJ, Zhao Y, Duyvesteyn HME, López-Camacho C, Slon-Campos J, Walter TS, Skelly D, Johnson SA, Ritter TG, Mason C, Costa Clemens SA, Gomes Naveca F, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Temperton N, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert SC, Malik T, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Baillie V, Serafin N, Ditse Z, Da Silva K, Paterson NG, Williams MA, Hall DR, Madhi S, Nunes MC, Goulder P, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell 184 4220-4236.e13 (2021)
  2. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L, Ho DD. iScience 26 108254 (2023)
  3. Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. Chi X, Xia L, Zhang G, Chi X, Huang B, Zhang Y, Chen Z, Han J, Wu L, Li Z, Sun H, Huang P, Yu C, Chen W, Zhou Q. Cell Discov 9 37 (2023)
  4. Identifying vaccine escape sites via statistical comparisons of short-term molecular dynamics. Rajendran M, Ferran MC, Babbitt GA. Biophys Rep (N Y) 2 100056 (2022)
  5. research-article Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces. Lubin JH, Markosian C, Balamurugan D, Pasqualini R, Arap W, Burley SK, Khare SD. bioRxiv 2021.12.12.472313 (2021)


Reviews citing this publication (102)

  1. The T cell immune response against SARS-CoV-2. Moss P. Nat Immunol 23 186-193 (2022)
  2. The biological and clinical significance of emerging SARS-CoV-2 variants. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. Nat Rev Genet 22 757-773 (2021)
  3. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Clin Microbiol Infect 28 202-221 (2022)
  4. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG. J Med Virol 94 1825-1832 (2022)
  5. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Rev Med Virol 32 e2381 (2022)
  6. The emergence, genomic diversity and global spread of SARS-CoV-2. Li J, Lai S, Gao GF, Shi W. Nature 600 408-418 (2021)
  7. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Heinz FX, Stiasny K. NPJ Vaccines 6 104 (2021)
  8. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS. Front Immunol 12 809244 (2021)
  9. Impact of the Delta variant on vaccine efficacy and response strategies. Bian L, Gao Q, Gao F, Wang Q, He Q, Wu X, Mao Q, Xu M, Liang Z. Expert Rev Vaccines 20 1201-1209 (2021)
  10. SARS-COV-2 Variants: Differences and Potential of Immune Evasion. Hirabara SM, Serdan TDA, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, Curi R, Durigon EL. Front Cell Infect Microbiol 11 781429 (2021)
  11. The germinal centre B cell response to SARS-CoV-2. Laidlaw BJ, Ellebedy AH. Nat Rev Immunol 22 7-18 (2022)
  12. The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. Tian D, Sun Y, Zhou J, Ye Q. Front Immunol 12 751778 (2021)
  13. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, Liang KH, Hsieh TY, Wu HC. J Biomed Sci 29 1 (2022)
  14. Genomic surveillance to combat COVID-19: challenges and opportunities. Robishaw JD, Alter SM, Solano JJ, Shih RD, DeMets DL, Maki DG, Hennekens CH. Lancet Microbe 2 e481-e484 (2021)
  15. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, Lowery P, Smith F, Dhanasekaran M, Moore T. Vaccines (Basel) 9 1195 (2021)
  16. The global epidemic of SARS-CoV-2 variants and their mutational immune escape. Tian D, Sun Y, Zhou J, Ye Q. J Med Virol 94 847-857 (2022)
  17. Antibody-mediated neutralization of SARS-CoV-2. Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Immunity 55 925-944 (2022)
  18. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Mittal A, Khattri A, Verma V. PLoS Pathog 18 e1010260 (2022)
  19. Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies. Noori M, Nejadghaderi SA, Arshi S, Carson-Chahhoud K, Ansarin K, Kolahi AA, Safiri S. Rev Med Virol 32 e2277 (2022)
  20. Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Dhawan M, Sharma A, Priyanka, Thakur N, Rajkhowa TK, Choudhary OP. Hum Vaccin Immunother 18 2068883 (2022)
  21. SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19. Li M, Lou F, Fan H. Signal Transduct Target Ther 6 349 (2021)
  22. Vaccines for COVID-19: Where do we stand in 2021? Sharma K, Koirala A, Nicolopoulos K, Chiu C, Wood N, Britton PN. Paediatr Respir Rev 39 22-31 (2021)
  23. SARS-CoV-2: Evolution and Emergence of New Viral Variants. Flores-Vega VR, Monroy-Molina JV, Jiménez-Hernández LE, Torres AG, Santos-Preciado JI, Rosales-Reyes R. Viruses 14 653 (2022)
  24. SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. Jhun H, Park HY, Hisham Y, Song CS, Kim S. Immune Netw 21 e32 (2021)
  25. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Ning Q, Wu D, Wang X, Xi D, Chen T, Chen G, Wang H, Lu H, Wang M, Zhu L, Hu J, Liu T, Ma K, Han M, Luo X. Signal Transduct Target Ther 7 57 (2022)
  26. Two Years into the COVID-19 Pandemic: Lessons Learned. da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, de Magalhães JJF, Vigar JRJ, Silva-Júnior A, Kohl A, Pardee K, Pena L. ACS Infect Dis 8 1758-1814 (2022)
  27. The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. Vaccines (Basel) 10 1926 (2022)
  28. B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. Zhan Y, Yin H, Yin JY. Int J Biol Sci 18 1844-1851 (2022)
  29. COVID-19: A systematic review and update on prevention, diagnosis, and treatment. Aghamirza Moghim Aliabadi H, Eivazzadeh-Keihan R, Beig Parikhani A, Fattahi Mehraban S, Maleki A, Fereshteh S, Bazaz M, Zolriasatein A, Bozorgnia B, Rahmati S, Saberi F, Yousefi Najafabadi Z, Damough S, Mohseni S, Salehzadeh H, Khakyzadeh V, Madanchi H, Kardar GA, Zarrintaj P, Saeb MR, Mozafari M. MedComm (2020) 3 e115 (2022)
  30. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, Wu J, Luo Z. Comput Struct Biotechnol J 20 824-837 (2022)
  31. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. Hoteit R, Yassine HM. Vaccines (Basel) 10 919 (2022)
  32. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19. Kumar A, Parashar R, Kumar S, Faiq MA, Kumari C, Kulandhasamy M, Narayan RK, Jha RK, Singh HN, Prasoon P, Pandey SN, Kant K. J Med Virol 94 1300-1314 (2022)
  33. SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. Singh DD, Parveen A, Yadav DK. Front Cell Infect Microbiol 11 777212 (2021)
  34. The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. Machado BAS, Hodel KVS, Fonseca LMDS, Pires VC, Mascarenhas LAB, da Silva Andrade LPC, Moret MA, Badaró R. Vaccines (Basel) 10 591 (2022)
  35. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Hu FH, Jia YJ, Zhao DY, Fu XL, Zhang WQ, Tang W, Hu SQ, Wu H, Ge MW, Du W, Shen WQ, Zhu B, Chen HL. Clin Microbiol Infect 29 835-844 (2023)
  36. Protective neutralizing epitopes in SARS-CoV-2. Liu H, Wilson IA. Immunol Rev 310 76-92 (2022)
  37. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. Ghimire D, Han Y, Lu M. Viruses 14 1255 (2022)
  38. SARS-CoV-2 variants - Evolution, spike protein, and vaccines. Chen KK, Tsung-Ning Huang D, Huang LM, Huang LM. Biomed J 45 573-579 (2022)
  39. Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Xiang Q, Li L, Wu J, Tian M, Fu Y. Microbiol Res 258 126993 (2022)
  40. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives. Quiros-Roldan E, Amadasi S, Zanella I, Degli Antoni M, Storti S, Tiecco G, Castelli F. Pharmaceuticals (Basel) 14 1272 (2021)
  41. Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. Pondé RAA. Virology 572 44-54 (2022)
  42. Human Organoids and Organs-on-Chips for Addressing COVID-19 Challenges. Wang Y, Wang P, Qin J. Adv Sci (Weinh) 9 e2105187 (2022)
  43. The Immune Response to SARS-CoV-2 and Variants of Concern. Torbati E, Krause KL, Ussher JE. Viruses 13 1911 (2021)
  44. Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. da Silva SJR, de Lima SC, da Silva RC, Kohl A, Pena L. Front Med (Lausanne) 8 836826 (2021)
  45. Wastewater-Based Epidemiology for Community Monitoring of SARS-CoV-2: Progress and Challenges. Kumblathan T, Liu Y, Uppal GK, Hrudey SE, Li XF. ACS Environ Au 1 18-31 (2021)
  46. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. Akinosoglou K, Rigopoulos EA, Kaiafa G, Daios S, Karlafti E, Ztriva E, Polychronopoulos G, Gogos C, Savopoulos C. Viruses 15 118 (2022)
  47. Advances in mRNA and other vaccines against MERS-CoV. Tai W, Zhang X, Yang Y, Zhu J, Du L. Transl Res 242 20-37 (2022)
  48. Defending against SARS-CoV-2: The T cell perspective. Almendro-Vázquez P, Laguna-Goya R, Paz-Artal E. Front Immunol 14 1107803 (2023)
  49. Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. de Souza AS, de Freitas Amorim VM, Guardia GDA, Dos Santos FF, Ulrich H, Galante PAF, de Souza RF, Guzzo CR. Viruses 14 827 (2022)
  50. The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance. Soh SM, Kim Y, Kim C, Jang US, Lee HR. J Microbiol 59 807-818 (2021)
  51. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  52. COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development. Vo GV, Bagyinszky E, An SSA. Microorganisms 10 598 (2022)
  53. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. Zhou J, Liu Z, Zhang G, Xu W, Xing L, Lu L, Wang Q, Jiang S. J Med Virol 95 e28172 (2023)
  54. Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. Hafiz I, Illian DN, Meila O, Utomo ARH, Susilowati A, Susetya IE, Desrita D, Siregar GA, Basyuni M. Vaccines (Basel) 10 82 (2022)
  55. Efficacy and Safety of COVID-19 Vaccines-An Update. Sharma E, Revinipati S, Bhandari S, Thakur S, Goyal S, Ghose A, Bajpai S, Muhammad W, Boussios S. Diseases 10 112 (2022)
  56. Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. Sarzani R, Spannella F, Giulietti F, Di Pentima C, Giordano P, Giacometti A. Intern Emerg Med 17 329-338 (2022)
  57. SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19. Mohseni Afshar Z, Tavakoli Pirzaman A, Karim B, Rahimipour Anaraki S, Hosseinzadeh R, Sanjari Pireivatlou E, Babazadeh A, Hosseinzadeh D, Miri SR, Sio TT, Sullman MJM, Barary M, Ebrahimpour S. Diagnostics (Basel) 13 559 (2023)
  58. The future of COVID-19: A vaccine review. Vashi AP, Coiado OC. J Infect Public Health 14 1461-1465 (2021)
  59. Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection. Serpeloni JM, Lima Neto QA, Lucio LC, Ramão A, Carvalho de Oliveira J, Gradia DF, Malheiros D, Ferrasa A, Marchi R, Figueiredo DLA, Silva WA, Ribeiro EMSF, Cólus IMS, Cavalli LR. Immunobiology 226 152130 (2021)
  60. Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. Al-Tawfiq JA, Koritala T, Alhumaid S, Barry M, Alshukairi AN, Temsah MH, Al Mutair A, Rabaan A, Tirupathi R, Gautret P. Infection 50 583-596 (2022)
  61. Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies. Gattinger P, Ohradanova-Repic A, Valenta R. Int J Mol Sci 24 5352 (2023)
  62. Interspecies Jumping of Bat Coronaviruses. Wong ACP, Lau SKP, Woo PCY. Viruses 13 2188 (2021)
  63. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation. van der Straten K, van Gils MJ, de Taeye SW, de Bree GJ. Front Med Technol 4 867982 (2022)
  64. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Bian L, Liu J, Gao F, Gao Q, He Q, Mao Q, Wu X, Xu M, Liang Z. Hum Vaccin Immunother 18 2057161 (2022)
  65. Tissue immunity to SARS-CoV-2: Role in protection and immunopathology. Rybkina K, Davis-Porada J, Farber DL. Immunol Rev 309 25-39 (2022)
  66. Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by Tissue-Resident CD4 Helper T Cells. Son YM, Sun J. Cells 10 2355 (2021)
  67. A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Mattoo SS, Myoung J. J Microbiol Biotechnol 31 1601-1614 (2021)
  68. Consecutive Hits of COVID-19 in India: The Mystery of Plummeting Cases and Current Scenario. Suvvari TK, P C, Kuppili S, Kandi V, Kutikuppala LVS, Kandula VDK, Mishra S, Sarangi AK, Mohapatra RK, Dhama K. Arch Razi Inst 76 1165-1174 (2021)
  69. Global trends in COVID-19. Zhou CM, Qin XR, Yan LN, Jiang Y, Yu XJ. Infect Med (Beijing) 1 31-39 (2022)
  70. Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air. Ramasamy R. Int J Mol Sci 22 7919 (2021)
  71. Application of omics technology to combat the COVID-19 pandemic. Yang J, Yan Y, Zhong W. MedComm (2020) 2 381-401 (2021)
  72. Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. Delshad M, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. Int Immunopharmacol 111 109128 (2022)
  73. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. Liang HY, Wu Y, Yau V, Yin HX, Lowe S, Bentley R, Ahmed MA, Zhao W, Sun C. Vaccines (Basel) 10 1538 (2022)
  74. New insights into human immune memory from SARS-CoV-2 infection and vaccination. Hartley GE, Edwards ESJ, O'Hehir RE, van Zelm MC. Allergy 77 3553-3566 (2022)
  75. COVID-19: the possibility, ways, mechanisms, and interruptions of mother-to-child transmission. Wang J, Dong W. Arch Gynecol Obstet 307 1687-1696 (2023)
  76. Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review. Shaheen N, Mohamed A, Attalla A, Diab RA, Swed S, Nashwan AJ, Rababah AA, Hefnawy MT, Soliman Y, Abdelwahab OA, Desouki MT, Khaity A, Shaheen A, Ramadan A, Meshref M. Infect Drug Resist 15 6317-6330 (2022)
  77. Epidemiology Features and Effectiveness of Vaccination and Non-Pharmaceutical Interventions of Delta and Lambda SARS-CoV-2 Variants. Bai W, Gu Y, Liu H, Zhou L. China CDC Wkly 3 977-982 (2021)
  78. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. Pavan M, Moro S. Int J Mol Sci 24 4401 (2023)
  79. Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. Zhang M, Gong Y, Jiao S. Future Virol (2022)
  80. Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19. Wang SC, Zhang F, Zhu H, Yang H, Liu Y, Wang P, Parpura V, Wang YF. Front Endocrinol (Lausanne) 13 799521 (2022)
  81. T cell immune memory after covid-19 and vaccination. Wang L, Nicols A, Turtle L, Richter A, Duncan CJ, Dunachie SJ, Klenerman P, Payne RP. BMJ Med 2 e000468 (2023)
  82. Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern. Al-Fattah Yahaya AA, Khalid K, Lim HX, Poh CL. Viruses 15 624 (2023)
  83. Evolution of SARS-CoV-2-specific CD4+ T cell epitopes. Brand M, Keşmir C. Immunogenetics 75 283-293 (2023)
  84. Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development. Zhao X, Chen D, Li X, Griffith L, Chang J, An P, Guo JT. J Mol Biol 434 167438 (2022)
  85. Neutralizing and enhancing antibodies against SARS-CoV-2. Liu Y, Arase H. Inflamm Regen 42 58 (2022)
  86. Biomimetic Nanotechnology for SARS-CoV-2 Treatment. Li S, Liu X, Liu G, Liu C. Viruses 15 596 (2023)
  87. Characteristics and management of SARS-CoV-2 delta variant-induced COVID-19 infections from May to October 2021 in China: post-vaccination infection cases. Xiang B, Zhang Y, Ling Q, Xie Z, Li N, Wu D. Am J Transl Res 14 3603-3609 (2022)
  88. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion. Xue S, Han Y, Wu F, Wang Q. Protein Cell 15 403-418 (2024)
  89. Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. Gao L, Mu X, Jiao YM, Wang FS. Infect Dis Immun 2 29-33 (2022)
  90. SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants. Hattab D, Amer MFA, Al-Alami ZM, Bakhtiar A. Infection 52 767-786 (2024)
  91. Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Pitsillou E, Yu Y, Beh RC, Liang JJ, Hung A, Karagiannis TC. Clin Exp Med 23 3277-3298 (2023)
  92. Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review. Yoon E, Kim D, Jeon H, Kwon Y, Jang Y, Kim S, Hwang KY. Comput Struct Biotechnol J 20 3533-3544 (2022)
  93. [The different phases of molecular and antigenic evolution of SARS-CoV-2 viruses during the 20 months following its emergence]. Lina B. Bull Acad Natl Med 206 87-99 (2022)
  94. Application of animal models to compare and contrast the virulence of current and future potential SARS-CoV-2 variants. Ding Z, Chen T, Lan J, Wong G. Biosaf Health 4 154-160 (2022)
  95. How concerning is a SARS-CoV-2 variant of concern? Computational predictions and the variants labeling system. Ashoor D, Marzouq M, Trabelsi K, Chlif S, Abotalib N, Khalaf NB, Ramadan AR, Fathallah MD. Front Cell Infect Microbiol 12 868205 (2022)
  96. Advancements in the Development of Anti-SARS-CoV-2 Therapeutics. Huang J, Ma Q, Su Z, Cheng X. Int J Mol Sci 25 10820 (2024)
  97. Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Jiang C, Jiang K, Li X, Zhang N, Zhu W, Meng L, Zhang Y, Lu S. J Pharm Anal 13 1-10 (2023)
  98. Insights into COVID-19 vaccines development: Translation from benchside to bedside. Houssein M, Al Hossainy AEA, Al Soussi J, El Batch J, El-Samadi L, El Imam S, Fakih R, Dakdouk H, Khalil M. Health Sci Rev (Oxf) 4 100040 (2022)
  99. Molecular characterization of SARS-CoV-2 nucleocapsid protein. Huang Y, Chen J, Chen S, Huang C, Li B, Li J, Jin Z, Zhang Q, Pan P, Du W, Liu L, Liu Z. Front Cell Infect Microbiol 14 1415885 (2024)
  100. Potential zoonotic spillover at the human-animal interface: A mini-review. Fauziah I, Nugroho HA, Yanthi ND, Tiffarent R, Saputra S. Vet World 17 289-302 (2024)
  101. Structural Requirements and Plasticity of Receptor-Binding Domain in Human Coronavirus Spike. Li Y, Zheng P, Liu T, Shi C, Wang B, Xu Y, Jin T. Front Mol Biosci 9 930931 (2022)
  102. The Mechanism of bnAb Production and Its Application in Mutable Virus Broad-Spectrum Vaccines: Inspiration from HIV-1 Broad Neutralization Research. Zhang X, Zhou Z. Vaccines (Basel) 11 1143 (2023)

Articles citing this publication (370)

  1. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H. Science 376 eabn4947 (2022)
  2. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A, Nutalai R, Wang B, Dijokaite A, Khan S, Avinoam O, Bahar M, Skelly D, Adele S, Johnson SA, Amini A, Ritter TG, Mason C, Dold C, Pan D, Assadi S, Bellass A, Omo-Dare N, Koeckerling D, Flaxman A, Jenkin D, Aley PK, Voysey M, Costa Clemens SA, Naveca FG, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Baillie V, Serafin N, Kwatra G, Da Silva K, Madhi SA, Nunes MC, Malik T, Openshaw PJM, Baillie JK, Semple MG, Townsend AR, Huang KA, Tan TK, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Constantinides B, Webster H, Crook D, Pollard AJ, Lambe T, OPTIC Consortium, ISARIC4C Consortium, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Schreiber G, Stuart DI, Screaton GR. Cell 185 467-484.e15 (2022)
  3. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, Lundgreen KA, Reynaldi A, Khoury DS, Pattekar A, Gouma S, Kuri-Cervantes L, Hicks P, Dysinger S, Hicks A, Sharma H, Herring S, Korte S, Baxter AE, Oldridge DA, Giles JR, Weirick ME, McAllister CM, Awofolaju M, Tanenbaum N, Drapeau EM, Dougherty J, Long S, D'Andrea K, Hamilton JT, McLaughlin M, Williams JC, Adamski S, Kuthuru O, UPenn COVID Processing Unit‡, Frank I, Betts MR, Vella LA, Grifoni A, Weiskopf D, Sette A, Hensley SE, Davenport MP, Bates P, Luning Prak ET, Greenplate AR, Wherry EJ. Science 374 abm0829 (2021)
  4. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, Liu C, Mentzer AJ, Supasa P, Duyvesteyn HME, Das R, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, Paterson NG, Williams MA, Hall DR, OPTIC Consortium, ISARIC4C Consortium, Fry EE, Huo J, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell 185 2422-2433.e13 (2022)
  5. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Khoury DS, Davenport MP. Lancet Microbe 3 e52-e61 (2022)
  6. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, Meardon N, Faustini S, Al-Taei S, Moore SC, Tipton T, Hering LM, Angyal A, Brown R, Nicols AR, Gillson N, Dobson SL, Amini A, Supasa P, Cross A, Bridges-Webb A, Reyes LS, Linder A, Sandhar G, Kilby JA, Tyerman JK, Altmann T, Hornsby H, Whitham R, Phillips E, Malone T, Hargreaves A, Shields A, Saei A, Foulkes S, Stafford L, Johnson S, Wootton DG, Conlon CP, Jeffery K, Matthews PC, Frater J, Deeks AS, Pollard AJ, Brown A, Rowland-Jones SL, Mongkolsapaya J, Barnes E, Hopkins S, Hall V, Dold C, Duncan CJA, Richter A, Carroll M, Screaton G, de Silva TI, Turtle L, Klenerman P, Dunachie S, PITCH Consortium. Cell 184 5699-5714.e11 (2021)
  7. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, Guan WJ, Gan L, Li YL, Liu WH, Dong H, Miao YT, Fan SJ, Zhang ZB, Zhang DM, Zhong NS. Emerg Microbes Infect 10 1751-1759 (2021)
  8. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K. J Autoimmun 124 102715 (2021)
  9. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, Wu Y, Behl S, Taylor JJ, Chakaraborty R, Johnson AJ, Shiavo DN, Utz JP, Reisenauer JS, Midthun DE, Mullon JJ, Edell ES, Alameh MG, Borish L, Teague WG, Kaplan MH, Weissman D, Kern R, Hu H, Vassallo R, Liu SL, Sun J. Sci Immunol 7 eadd4853 (2022)
  10. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. Davis C, Logan N, Tyson G, Orton R, Harvey WT, Perkins JS, Mollett G, Blacow RM, COVID-19 Genomics UK (COG-UK) Consortium, Peacock TP, Barclay WS, Cherepanov P, Palmarini M, Murcia PR, Patel AH, Robertson DL, Haughney J, Thomson EC, Willett BJ, COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators. PLoS Pathog 17 e1010022 (2021)
  11. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, Snyman J, Moyo-Gwete T, Wilkinson E, Bernstein M, Khan K, Hwa SH, Tilles SW, Singh L, Giandhari J, Mthabela N, Mazibuko M, Ganga Y, Gosnell BI, Karim SSA, Hanekom W, Van Voorhis WC, Ndung'u T, COMMIT-KZN Team, Lessells RJ, Moore PL, Moosa MS, de Oliveira T, Sigal A. Cell Host Microbe 30 154-162.e5 (2022)
  12. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, Adele S, Adland E, Brown H, Medawar Laboratory Team, Tipton T, Stafford L, Mentzer AJ, Johnson SA, Amini A, OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group, Tan TK, Schimanski L, Huang KA, Rijal P, PITCH (Protective Immunity T cells in Health Care Worker) Study Group, C-MORE/PHOSP-C Group, Frater J, Goulder P, Conlon CP, Jeffery K, Dold C, Pollard AJ, Sigal A, de Oliveira T, Townsend AR, Klenerman P, Dunachie SJ, Barnes E, Carroll MW, James WS. Nat Commun 12 5061 (2021)
  13. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu SL. Sci Transl Med 14 eabn8057 (2022)
  14. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S, Marschalek R, Herrmann E, Helfritz FA, Wolf T, Goetsch U, Ciesek S. EBioMedicine 82 104158 (2022)
  15. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Loo YM, McTamney PM, Arends RH, Abram ME, Aksyuk AA, Diallo S, Flores DJ, Kelly EJ, Ren K, Roque R, Rosenthal K, Streicher K, Tuffy KM, Bond NJ, Cornwell O, Bouquet J, Cheng LI, Dunyak J, Huang Y, Rosenbaum AI, Pilla Reddy V, Andersen H, Carnahan RH, Crowe JE, Kuehne AI, Herbert AS, Dye JM, Bright H, Kallewaard NL, Pangalos MN, Esser MT. Sci Transl Med 14 eabl8124 (2022)
  16. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, Liu G, Yin Z, Chen JL, Lu Y, Wellington D, Wing PAC, Dominey-Foy DCC, Jin C, Wang W, Hamid MA, Fernandes RA, Wang B, Fries A, Zhuang X, Ashley N, Rostron T, Waugh C, Sopp P, Hublitz P, Beveridge R, Tan TK, Dold C, Kwok AJ, Rich-Griffin C, Dejnirattisa W, Liu C, Kurupati P, Nassiri I, Watson RA, Tong O, Taylor CA, Kumar Sharma P, Sun B, Curion F, Revale S, Garner LC, Jansen K, Ferreira RC, Attar M, Fry JW, Russell RA, COMBAT Consortium, Stauss HJ, James W, Townsend A, Ho LP, Klenerman P, Mongkolsapaya J, Screaton GR, Dendrou C, Sansom SN, Bashford-Rogers R, Chain B, Smith GL, McKeating JA, Fairfax BP, Bowness P, McMichael AJ, Ogg G, Knight JC, Dong T. Nat Immunol 23 50-61 (2022)
  17. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Wang X, Zhao X, Song J, Wu J, Zhu Y, Li M, Cui Y, Chen Y, Yang L, Liu J, Zhu H, Jiang S, Wang P. Emerg Microbes Infect 11 477-481 (2022)
  18. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, Huo J, Mentzer AJ, Duyvesteyn HME, Dijokaite-Guraliuc A, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, OPTIC consortium, ISARIC4C consortium, Paterson NG, Williams MA, Hall DR, Mongkolsapaya J, Fry EE, Dejnirattisai W, Ren J, Stuart DI, Screaton GR. Cell 185 2116-2131.e18 (2022)
  19. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Keeton R, Richardson SI, Moyo-Gwete T, Hermanus T, Tincho MB, Benede N, Manamela NP, Baguma R, Makhado Z, Ngomti A, Motlou T, Mennen M, Chinhoyi L, Skelem S, Maboreke H, Doolabh D, Iranzadeh A, Otter AD, Brooks T, Noursadeghi M, Moon JC, Grifoni A, Weiskopf D, Sette A, Blackburn J, Hsiao NY, Williamson C, Riou C, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Moore PL, Burgers WA. Cell Host Microbe 29 1611-1619.e5 (2021)
  20. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. Shen Z, Ratia K, Cooper L, Kong D, Lee H, Kwon Y, Li Y, Alqarni S, Huang F, Dubrovskyi O, Rong L, Thatcher GRJ, Xiong R. J Med Chem 65 2940-2955 (2022)
  21. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Wang Y, Liu C, Zhang C, Wang Y, Hong Q, Xu S, Li Z, Yang Y, Huang Z, Cong Y. Nat Commun 13 871 (2022)
  22. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. Kang M, Xin H, Yuan J, Ali ST, Liang Z, Zhang J, Hu T, Lau EH, Zhang Y, Zhang M, Cowling BJ, Li Y, Wu P. Euro Surveill 27 (2022)
  23. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettner I, Jimenez-Guardeño JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ. Nat Microbiol 6 1433-1442 (2021)
  24. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination. Yang W, Shaman J. J R Soc Interface 19 20210900 (2022)
  25. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Martinez DR, Schäfer A, Gobeil S, Li D, De la Cruz G, Parks R, Lu X, Barr M, Stalls V, Janowska K, Beaudoin E, Manne K, Mansouri K, Edwards RJ, Cronin K, Yount B, Anasti K, Montgomery SA, Tang J, Golding H, Shen S, Zhou T, Kwong PD, Graham BS, Mascola JR, Montefiori DC, Alam SM, Sempowski G, Sempowski GD, Khurana S, Wiehe K, Saunders KO, Acharya P, Haynes BF, Baric RS. Sci Transl Med 14 eabj7125 (2022)
  26. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. Tsai SJ, Atai NA, Cacciottolo M, Nice J, Salehi A, Guo C, Sedgwick A, Kanagavelu S, Gould SJ. J Biol Chem 297 101266 (2021)
  27. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. Dalvie NC, Rodriguez-Aponte SA, Hartwell BL, Tostanoski LH, Biedermann AM, Crowell LE, Kaur K, Kumru OS, Carter L, Yu J, Chang A, McMahan K, Courant T, Lebas C, Lemnios AA, Rodrigues KA, Silva M, Johnston RS, Naranjo CA, Tracey MK, Brady JR, Whittaker CA, Yun D, Brunette N, Wang JY, Walkey C, Fiala B, Kar S, Porto M, Lok M, Andersen H, Lewis MG, Love KR, Camp DL, Silverman JM, Kleanthous H, Joshi SB, Volkin DB, Dubois PM, Collin N, King NP, Barouch DH, Irvine DJ, Love JC. Proc Natl Acad Sci U S A 118 e2106845118 (2021)
  28. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Lancet Respir Med 10 972-984 (2022)
  29. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF. Cell 185 2265-2278.e14 (2022)
  30. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Riou C, Keeton R, Moyo-Gwete T, Hermanus T, Kgagudi P, Baguma R, Valley-Omar Z, Smith M, Tegally H, Doolabh D, Iranzadeh A, Tyers L, Mutavhatsindi H, Tincho MB, Benede N, Marais G, Chinhoyi LR, Mennen M, Skelem S, du Bruyn E, Stek C, South African cellular immunity network, de Oliveira T, Williamson C, Moore PL, Wilkinson RJ, Ntusi NAB, Burgers WA. Sci Transl Med 14 eabj6824 (2022)
  31. Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. Bushman M, Kahn R, Taylor BP, Lipsitch M, Hanage WP. Cell 184 6229-6242.e18 (2021)
  32. RCSB Protein Data Bank: Celebrating 50 years of the PDB with new tools for understanding and visualizing biological macromolecules in 3D. Burley SK, Bhikadiya C, Bi C, Bittrich S, Chen L, Crichlow GV, Duarte JM, Dutta S, Fayazi M, Feng Z, Flatt JW, Ganesan SJ, Goodsell DS, Ghosh S, Kramer Green R, Guranovic V, Henry J, Hudson BP, Lawson CL, Liang Y, Lowe R, Peisach E, Persikova I, Piehl DW, Rose Y, Sali A, Segura J, Sekharan M, Shao C, Vallat B, Voigt M, Westbrook JD, Whetstone S, Young JY, Zardecki C. Protein Sci 31 187-208 (2022)
  33. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH, Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S, Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP, Maniatis T, Perlin DS, Kreiswirth BN. mSphere 6 e0048021 (2021)
  34. A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. Greaney AJ, Starr TN, Eguia RT, Loes AN, Khan K, Karim F, Cele S, Bowen JE, Logue JK, Corti D, Veesler D, Chu HY, Sigal A, Bloom JD. PLoS Pathog 18 e1010248 (2022)
  35. Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. Nabel KG, Clark SA, Shankar S, Pan J, Clark LE, Yang P, Coscia A, McKay LGA, Varnum HH, Brusic V, Tolan NV, Zhou G, Desjardins M, Turbett SE, Kanjilal S, Sherman AC, Dighe A, LaRocque RC, Ryan ET, Tylek C, Cohen-Solal JF, Darcy AT, Tavella D, Clabbers A, Fan Y, Griffiths A, Correia IR, Seagal J, Baden LR, Charles RC, Abraham J. Science 375 eabl6251 (2022)
  36. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. Ying B, Whitener B, VanBlargan LA, Hassan AO, Shrihari S, Liang CY, Karl CE, Mackin S, Chen RE, Kafai NM, Wilks SH, Smith DJ, Carreño JM, Singh G, Krammer F, Carfi A, Elbashir SM, Edwards DK, Thackray LB, Diamond MS. Sci Transl Med 14 eabm3302 (2022)
  37. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Liu Z, Zhou J, Xu W, Deng W, Wang Y, Wang M, Wang Q, Hsieh M, Dong J, Wang X, Huang W, Xing L, He M, Tao C, Xie Y, Zhang Y, Wang Y, Zhao J, Yuan Z, Qin C, Jiang S, Lu L. Cell Res 32 269-287 (2022)
  38. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. van der Straten K, Guerra D, van Gils MJ, Bontjer I, Caniels TG, van Willigen HDG, Wynberg E, Poniman M, Burger JA, Bouhuijs JH, van Rijswijk J, Olijhoek W, Liesdek MH, Lavell AHA, Appelman B, Sikkens JJ, Bomers MK, Han AX, Nichols BE, Prins M, Vennema H, Reusken C, de Jong MD, de Bree GJ, Russell CA, Eggink D, Sanders RW. Immunity 55 1725-1731.e4 (2022)
  39. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, Martinez DR, Giffin V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole AC, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Boon ACM, Baric RS, Mueller SO, Petsch B, Barouch DH. Nature 601 410-414 (2022)
  40. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Münn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. Cell Host Microbe 30 1231-1241.e6 (2022)
  41. Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. Wang Y, Xu C, Wang Y, Hong Q, Zhang C, Li Z, Xu S, Zuo Q, Liu C, Huang Z, Cong Y. Nat Commun 12 7345 (2021)
  42. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, Huang JH, Liu H, Ho YH, Lin F, Ding S, Liu Z, Wu HT, Huang CT, Lee YJ, Liu MC, Yang YC, Lu PL, Tsai HC, Lee CH, Shi ZY, Liu CE, Liao CH, Chang FY, Chen HC, Wang FD, Hou KL, Cheng J, Wang MS, Yang YT, Chiu HC, Jiang MH, Shih HY, Shen HY, Chang PY, Lan YR, Chen CT, Lin YL, Liang JJ, Liao CC, Chou YC, Morris MK, Hanson CV, Guirakhoo F, Hellerstein M, Yu HJ, King CC, Kemp T, Heppner DG, Monath TP. J Clin Invest 132 e157707 (2022)
  43. COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. Alhasan K, Aljamaan F, Temsah MH, Alshahrani F, Bassrawi R, Alhaboob A, Assiri R, Alenezi S, Alaraj A, Alhomoudi RI, Batais MA, Al-Eyadhy L, Halwani R, AbdulMajeed N, Al-Jedai A, Senjab A, Memish ZA, Al-Subaie S, Barry M, Al-Tawfiq JA. Healthcare (Basel) 9 1566 (2021)
  44. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3. Huang M, Wu L, Zheng A, Xie Y, He Q, Rong X, Han P, Du P, Han P, Zhang Z, Zhao R, Jia Y, Li L, Bai B, Hu Z, Hu S, Niu S, Hu Y, Liu H, Liu B, Cui K, Li W, Zhao X, Liu K, Qi J, Wang Q, Gao GF. Immunity 55 1501-1514.e3 (2022)
  45. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. Liu C, Zhou D, Nutalai R, Duyvesteyn HME, Tuekprakhon A, Ginn HM, Dejnirattisai W, Supasa P, Mentzer AJ, Wang B, Case JB, Zhao Y, Skelly DT, Chen RE, Johnson SA, Ritter TG, Mason C, Malik T, Temperton N, Paterson NG, Williams MA, Hall DR, Clare DK, Howe A, Goulder PJR, Fry EE, Diamond MS, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell Host Microbe 30 53-68.e12 (2022)
  46. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Corbett KS, Werner AP, Connell SO, Gagne M, Lai L, Moliva JI, Flynn B, Choi A, Koch M, Foulds KE, Andrew SF, Flebbe DR, Lamb E, Nurmukhambetova ST, Provost SJ, Bock KW, Minai M, Nagata BM, Ry AV, Flinchbaugh Z, Johnston TS, Mokhtari EB, Mudvari P, Henry AR, Laboune F, Chang B, Porto M, Wear J, Alvarado GS, Boyoglu-Barnum S, Todd JM, Bart B, Cook A, Dodson A, Pessaint L, Steingrebe K, Elbashir S, Sriparna M, Pekosz A, Andersen H, Wu K, Edwards DK, Kar S, Lewis MG, Boritz E, Moore IN, Carfi A, Suthar MS, McDermott A, Roederer M, Nason MC, Sullivan NJ, Douek DC, Graham BS, Seder RA. Nat Immunol 22 1306-1315 (2021)
  47. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. Faulkner N, Ng KW, Wu MY, Harvey R, Margaritis M, Paraskevopoulou S, Houlihan C, Hussain S, Greco M, Bolland W, Warchal S, Heaney J, Rickman H, Spyer M, Frampton D, Byott M, de Oliveira T, Sigal A, Kjaer S, Swanton C, Gandhi S, Beale R, Gamblin SJ, McCauley JW, Daniels RS, Howell M, Bauer D, Nastouli E, Kassiotis G. Elife 10 e69317 (2021)
  48. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. Lau EH, Hui DS, Tsang OT, Chan WH, Kwan MY, Chiu SS, Cheng SM, Ko RL, Li JK, Chaothai S, Tsang CH, Poon LL, Peiris M. EClinicalMedicine 41 101174 (2021)
  49. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Newman J, Thakur N, Peacock TP, Bialy D, Elrefaey AME, Bogaardt C, Horton DL, Ho S, Kankeyan T, Carr C, Hoschler K, Barclay WS, Amirthalingam G, Brown KE, Charleston B, Bailey D. Nat Microbiol 7 1180-1188 (2022)
  50. Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant. Jawad B, Adhikari P, Podgornik R, Ching WY. J Phys Chem Lett 13 3915-3921 (2022)
  51. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Hueso T, Godron AS, Lanoy E, Pacanowski J, Levi LI, Gras E, Surgers L, Guemriche A, Meynard JL, Pirenne F, Idri S, Tiberghien P, Morel P, Besson C, Duléry R, Lamure S, Hermine O, Gagneux-Brunon A, Freymond N, Grabar S, Lacombe K. Leukemia 36 1025-1034 (2022)
  52. SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron. Laurie MT, Liu J, Sunshine S, Peng J, Black D, Mitchell AM, Mann SA, Pilarowski G, Zorn KC, Rubio L, Bravo S, Marquez C, Sabatino JJ, Mittl K, Petersen M, Havlir D, DeRisi J. J Infect Dis 225 1909-1914 (2022)
  53. The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England. Paton RS, Overton CE, Ward T. Sci Transl Med 14 eabo5395 (2022)
  54. COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). Yang W, Shaman JL. Elife 11 e78933 (2022)
  55. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. Zeng C, Evans JP, Faraone JN, Qu P, Zheng YM, Saif L, Oltz EM, Lozanski G, Gumina RJ, Liu SL. mBio 12 e0251021 (2021)
  56. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. Touret F, Baronti C, Bouzidi HS, de Lamballerie X. Sci Rep 12 4683 (2022)
  57. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. Lou F, Li M, Pang Z, Jiang L, Guan L, Tian L, Hu J, Fan J, Fan H. Front Immunol 12 744242 (2021)
  58. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn HM, Das R, Supasa P, Selvaraj M, Nutalai R, Tuekprakhon A, Duyvesteyn HME, Mentzer AJ, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Paterson NG, Williams MA, Hall DR, Plowright M, Newman TAH, Hornsby H, de Silva TI, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Pollard AJ, Lambe T, Goulder P, OPTIC consortium, ISARIC4C consortium, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell Rep 42 111903 (2023)
  59. Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. Shoukat A, Vilches TN, Moghadas SM, Sah P, Schneider EC, Shaff J, Ternier A, Chokshi DA, Galvani AP. Lancet Reg Health Am 5 100085 (2022)
  60. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors. Chen RE, Gorman MJ, Zhu DY, Carreño JM, Yuan D, VanBlargan LA, Burdess S, Lauffenburger DA, Kim W, Turner JS, Droit L, Handley SA, Chahin S, Deepak P, O'Halloran JA, Paley MA, Presti RM, Wu GF, Krammer F, Alter G, Ellebedy AH, Kim AHJ, Diamond MS. Med 2 1327-1341.e4 (2021)
  61. Editorial Will the COVID-19 pandemic end with the Delta and Omicron variants? Wang C, Han J. Environ Chem Lett 20 2215-2225 (2022)
  62. Characterization and functional interrogation of the SARS-CoV-2 RNA interactome. Labeau A, Fery-Simonian L, Lefevre-Utile A, Pourcelot M, Bonnet-Madin L, Soumelis V, Lotteau V, Vidalain PO, Amara A, Meertens L. Cell Rep 39 110744 (2022)
  63. Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. Wang Z, Zhou P, Muecksch F, Cho A, Ben Tanfous T, Canis M, Witte L, Johnson B, Raspe R, Schmidt F, Bednarski E, Da Silva J, Ramos V, Zong S, Turroja M, Millard KG, Yao KH, Shimeliovich I, Dizon J, Kaczynska A, Jankovic M, Gazumyan A, Oliveira TY, Caskey M, Gaebler C, Bieniasz PD, Hatziioannou T, Nussenzweig MC. J Exp Med 219 e20221006 (2022)
  64. Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. Tortorici MA, Walls AC, Joshi A, Park YJ, Eguia RT, Miranda MC, Kepl E, Dosey A, Stevens-Ayers T, Boeckh MJ, Telenti A, Lanzavecchia A, King NP, Corti D, Bloom JD, Veesler D. Cell 185 2279-2291.e17 (2022)
  65. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Bošnjak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt SI, Permanyer M, Patzer GE, Greorgiev H, Gutierrez Jauregui R, Tscherne A, Schwarz JH, Kalodimou G, Ssebyatika G, Ciurkiewicz M, Willenzon S, Bubke A, Ristenpart J, Ritter C, Tuchel T, Meyer Zu Natrup C, Shin DL, Clever S, Limpinsel L, Baumgärtner W, Krey T, Volz A, Sutter G, Förster R. Front Immunol 12 772240 (2021)
  66. Letter Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Arora P, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M. Cell Mol Immunol 18 2557-2559 (2021)
  67. Genetic Analysis of SARS-CoV-2 Variants in Mexico during the First Year of the COVID-19 Pandemic. Taboada B, Zárate S, Iša P, Boukadida C, Vazquez-Perez JA, Muñoz-Medina JE, Ramírez-González JE, Comas-García A, Grajales-Muñiz C, Rincón-Rubio A, Matías-Florentino M, Sanchez-Flores A, Mendieta-Condado E, Verleyen J, Barrera-Badillo G, Hernández-Rivas L, Mejía-Nepomuceno F, Martínez-Orozco JA, Becerril-Vargas E, López S, López-Martínez I, Ávila-Ríos S, Arias CF. Viruses 13 2161 (2021)
  68. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Balachandran H, Phetsouphanh C, Agapiou D, Adhikari A, Rodrigo C, Hammoud M, Shrestha LB, Keoshkerian E, Gupta M, Turville S, Christ D, King C, Sasson SC, Bartlett A, Grubor-Bauk B, Rawlinson W, Aggarwal A, Stella AO, Klemm V, Mina MM, Post JJ, Hudson B, Gilroy N, Konecny P, Ahlenstiel G, Dwyer DE, Sorrell TC, Kelleher A, Tedla N, Lloyd AR, Martinello M, Bull RA, COSIN Study Group. Cell Rep 38 110345 (2022)
  69. SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD, Beale S, Braithwaite I, Byrne T, Kovar J, Fragaszy E, Fong WLE, Geismar C, Patel P, Rodger A, Johnson AM, Hayward A. Nat Commun 13 4869 (2022)
  70. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. Walter JD, Scherer M, Hutter CAJ, Garaeva AA, Zimmermann I, Wyss M, Rheinberger J, Ruedin Y, Earp JC, Egloff P, Sorgenfrei M, Hürlimann LM, Gonda I, Meier G, Remm S, Thavarasah S, van Geest G, Bruggmann R, Zimmer G, Slotboom DJ, Paulino C, Plattet P, Seeger MA. EMBO Rep 23 e54199 (2022)
  71. Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. Cheng MH, Krieger JM, Banerjee A, Xiang Y, Kaynak B, Shi Y, Arditi M, Bahar I. iScience 25 103939 (2022)
  72. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Vikkurthi R, Ansari A, Pai AR, Jha SN, Sachan S, Pandit S, Nikam B, Kalia A, Jit BP, Parray HA, Singh S, Kshetrapal P, Wadhwa N, Shrivastava T, Coshic P, Kumar S, Sharma P, Sharma N, Taneja J, Pandey AK, Sharma A, Thiruvengadam R, Grifoni A, Weiskopf D, Sette A, Bhatnagar S, Gupta N. Nat Microbiol 7 974-985 (2022)
  73. SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. He P, Liu B, Gao X, Yan Q, Pei R, Sun J, Chen Q, Hou R, Li Z, Zhang Y, Zhao J, Sun H, Feng B, Wang Q, Yi H, Hu P, Li P, Zhang Y, Chen Z, Niu X, Zhong X, Jin L, Liu X, Qu K, Ciazynska KA, Carter AP, Briggs JAG, Chen J, Liu J, Chen X, He J, Chen L, Xiong X. Nat Microbiol 7 1635-1649 (2022)
  74. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. Angkasekwinai N, Sewatanon J, Niyomnaitham S, Phumiamorn S, Sukapirom K, Sapsutthipas S, Sirijatuphat R, Wittawatmongkol O, Senawong S, Mahasirimongkol S, Trisiriwanich S, Chokephaibulkit K. Vaccine X 10 100153 (2022)
  75. Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core. Pak AJ, Yu A, Ke Z, Briggs JAG, Voth GA. Nat Commun 13 1002 (2022)
  76. Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. Yilmaz IC, Ipekoglu EM, Bulbul A, Turay N, Yildirim M, Evcili I, Yilmaz NS, Guvencli N, Aydin Y, Gungor B, Saraydar B, Bartan AG, Ibibik B, Bildik T, Baydemir İ, Sanli HA, Kayaoglu B, Ceylan Y, Yildirim T, Abras I, Ayanoglu IC, Cam SB, Ciftci Dede E, Gizer M, Erganis O, Sarac F, Uzar S, Enul H, Adiay C, Aykut G, Polat H, Yildirim IS, Tekin S, Korukluoglu G, Zeytin HE, Korkusuz P, Gursel I, Gursel M. Allergy 77 258-270 (2022)
  77. High Seroprevalence of SARS-CoV-2 in White-Tailed Deer (Odocoileus virginianus) at One of Three Captive Cervid Facilities in Texas. Roundy CM, Nunez CM, Thomas LF, Auckland LD, Tang W, Richison JJ, Green BR, Hilton CD, Cherry MJ, Pauvolid-Corrêa A, Hamer GL, Cook WE, Hamer SA. Microbiol Spectr 10 e0057622 (2022)
  78. Probing the mutation independent interaction of DNA probes with SARS-CoV-2 variants through a combination of surface-enhanced Raman scattering and machine learning. Moitra P, Chaichi A, Abid Hasan SM, Dighe K, Alafeef M, Prasad A, Gartia MR, Pan D. Biosens Bioelectron 208 114200 (2022)
  79. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Yang Z, Wang Y, Jin Y, Zhu Y, Wu Y, Li C, Kong Y, Song W, Tian X, Zhan W, Huang A, Zhou S, Xia S, Tian X, Peng C, Chen C, Shi Y, Hu G, Du S, Wang Y, Xie Y, Jiang S, Lu L, Sun L, Song Y, Ying T. Signal Transduct Target Ther 6 378 (2021)
  80. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Wheatley AK, Pymm P, Esterbauer R, Dietrich MH, Lee WS, Drew D, Kelly HG, Chan LJ, Mordant FL, Black KA, Adair A, Tan HX, Juno JA, Wragg KM, Amarasena T, Lopez E, Selva KJ, Haycroft ER, Cooney JP, Venugopal H, Tan LL, O Neill MT, Allison CC, Cromer D, Davenport MP, Bowen RA, Chung AW, Pellegrini M, Liddament MT, Glukhova A, Subbarao K, Kent SJ, Tham WH. Cell Rep 37 109822 (2021)
  81. Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike - ACE2 complexes reveal distinct changes between both variants. Socher E, Heger L, Paulsen F, Zunke F, Arnold P. Comput Struct Biotechnol J 20 1168-1176 (2022)
  82. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AEL, Balachandran H, Mekonnen ZA, Al-Delfi Z, Abayasingam A, Agapiou D, Stella AO, Aggarwal A, Bouras G, Gummow J, Ferguson C, O'Connor S, McCartney EM, Lynn DJ, Maddern G, Gowans EJ, Reddi BAJ, Shaw D, Kok-Lim C, Beard MR, Weiskopf D, Sette A, Turville SG, Bull RA, Barry SC, Grubor-Bauk B. Cell Rep Med 3 100651 (2022)
  83. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. Spencer AJ, Morris S, Ulaszewska M, Powers C, Kailath R, Bissett C, Truby A, Thakur N, Newman J, Allen ER, Rudiansyah I, Liu C, Dejnirattisai W, Mongkolsapaya J, Davies H, Donnellan FR, Pulido D, Peacock TP, Barclay WS, Bright H, Ren K, Screaton G, McTamney P, Bailey D, Gilbert SC, Lambe T. EBioMedicine 77 103902 (2022)
  84. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. Lechmere T, Snell LB, Graham C, Seow J, Shalim ZA, Charalampous T, Alcolea-Medina A, Batra R, Nebbia G, Edgeworth JD, Malim MH, Doores KJ. mBio 13 e0379821 (2022)
  85. Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. Rodgers MA, Olivo A, Harris BJ, Lark C, Luo X, Berg MG, Meyer TV, Mohaimani A, Orf GS, Goldstein Y, Fox AS, Hirschhorn J, Glen WB, Nolte F, Landay A, Jennings C, Moy J, Servellita V, Chiu C, Batra R, Snell LB, Nebbia G, Douthwaite S, Tanuri A, Singh L, de Oliveira T, Ahouidi A, Mboup S, Cloherty GA. J Clin Virol 147 105080 (2022)
  86. Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Tomic A, Skelly DT, Ogbe A, O'Connor D, Pace M, Adland E, Alexander F, Ali M, Allott K, Azim Ansari M, Belij-Rammerstorfer S, Bibi S, Blackwell L, Brown A, Brown H, Cavell B, Clutterbuck EA, de Silva T, Eyre D, Lumley S, Flaxman A, Grist J, Hackstein CP, Halkerston R, Harding AC, Hill J, James T, Jay C, Johnson SA, Kronsteiner B, Lie Y, Linder A, Longet S, Marinou S, Matthews PC, Mellors J, Petropoulos C, Rongkard P, Sedik C, Silva-Reyes L, Smith H, Stockdale L, Taylor S, Thomas S, Tipoe T, Turtle L, Vieira VA, Wrin T, OPTIC Clinical Group, PITCH Study Group, C-MORE Group, Pollard AJ, Lambe T, Conlon CP, Jeffery K, Travis S, Goulder P, Frater J, Mentzer AJ, Stafford L, Carroll MW, James WS, Klenerman P, Barnes E, Dold C, Dunachie SJ. Nat Commun 13 1251 (2022)
  87. Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Trimpert J, Adler JM, Eschke K, Abdelgawad A, Firsching TC, Ebert N, Thao TTN, Gruber AD, Thiel V, Osterrieder N, Kunec D. Sci Adv 7 eabk0172 (2021)
  88. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sánchez-Sendra B, Albert E, Zulaica J, Torres I, Giménez E, Botija P, Beltrán MJ, Rodado C, Geller R, Navarro D. Sci Rep 12 3788 (2022)
  89. Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. Kang YF, Sun C, Sun J, Xie C, Zhuang Z, Xu HQ, Liu Z, Liu YH, Peng S, Yuan RY, Zhao JC, Zeng MS. Nat Commun 13 2674 (2022)
  90. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Wang M, Zhang L, Li Q, Wang B, Liang Z, Sun Y, Nie J, Wu J, Su X, Qu X, Li Y, Wang Y, Huang W. Emerg Microbes Infect 11 18-29 (2022)
  91. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. Wang B, Goh YS, Fong SW, Young BE, Ngoh EZX, Chavatte JM, Salleh SNM, Yeo NK, Amrun SN, Hor PX, Loh CY, Lee CY, Chan YH, Chang ZW, Tay MZ, Rouers A, Torres-Ruesta A, Carissimo G, Soh MK, Lee RTC, Xu Y, Pada S, Lin RTP, Leo YS, Lye DC, Maurer-Stroh S, Ng LFP, Renia L, Wang CI. Lancet Reg Health West Pac 15 100276 (2021)
  92. Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike. Cantoni D, Murray MJ, Kalemera MD, Dicken SJ, Stejskal L, Brown G, Lytras S, Coey JD, McKenna J, Bridgett S, Simpson D, Fairley D, Thorne LG, Reuschl AK, Forrest C, Ganeshalingham M, Muir L, Palor M, Jarvis L, Willett B, Power UF, McCoy LE, Jolly C, Towers GJ, Doores KJ, Robertson DL, Shepherd AJ, Reeves MB, Bamford CGG, Grove J. EMBO Rep 23 e54322 (2022)
  93. Genomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages. Zhou HY, Cheng YX, Xu L, Li JY, Tao CY, Ji CY, Han N, Yang R, Wu H, Li Y, Wu A. Comput Struct Biotechnol J 20 4015-4024 (2022)
  94. A second functional furin site in the SARS-CoV-2 spike protein. Zhang Y, Zhang L, Wu J, Yu Y, Liu S, Li T, Li Q, Ding R, Wang H, Nie J, Cui Z, Wang Y, Huang W, Wang Y. Emerg Microbes Infect 11 182-194 (2022)
  95. SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. Kuzmina A, Wattad S, Khalaila Y, Ottolenghi A, Rosental B, Engel S, Rosenberg E, Taube R. iScience 24 103467 (2021)
  96. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination. Pillaiyar T, Flury P, Krüger N, Su H, Schäkel L, Barbosa Da Silva E, Eppler O, Kronenberger T, Nie T, Luedtke S, Rocha C, Sylvester K, Petry MRI, McKerrow JH, Poso A, Pöhlmann S, Gütschow M, O'Donoghue AJ, Xu Y, Müller CE, Laufer SA. J Med Chem 65 9376-9395 (2022)
  97. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets. Liu Q, Wang H, Zhang H, Sui L, Li L, Xu W, Du S, Hao P, Jiang Y, Chen J, Qu X, Tian M, Zhao Y, Guo X, Wang X, Song W, Song G, Wei Z, Hou Z, Wang G, Sun M, Li X, Lu H, Zhuang X, Jin N, Zhao Y, Li C, Liao M. Proc Natl Acad Sci U S A 119 e2123065119 (2022)
  98. A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. Wang R, Sun C, Ma J, Yu C, Kong D, Chen M, Liu X, Zhao D, Gao S, Kou S, Sun L, Ge Z, Zhao J, Li K, Zhang T, Zhang Y, Luo C, Li X, Wang Y, Xie L. Vaccines (Basel) 10 702 (2022)
  99. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Zhou B, Zhou R, Tang B, Chan JF, Luo M, Peng Q, Yuan S, Liu H, Mok BW, Chen B, Wang P, Poon VK, Chu H, Chan CC, Tsang JO, Chan CC, Au KK, Man HO, Lu L, To KK, Chen H, Yuen KY, Dang S, Chen Z. Nat Commun 13 3589 (2022)
  100. A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants. Farley SE, Kyle JE, Leier HC, Bramer LM, Weinstein JB, Bates TA, Lee JY, Metz TO, Schultz C, Tafesse FG. Nat Commun 13 3487 (2022)
  101. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Zeng L, Liu Y, Nguyenla XH, Abbott TR, Han M, Zhu Y, Chemparathy A, Lin X, Chen X, Wang H, Rane DA, Spatz JM, Jain S, Rustagi A, Pinsky B, Zepeda AE, Kadina AP, Walker JA, Holden K, Temperton N, Cochran JR, Barron AE, Connolly MD, Blish CA, Lewis DB, Stanley SA, La Russa MF, Qi LS. Nat Commun 13 2766 (2022)
  102. Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. Frumkin LR, Lucas M, Scribner CL, Ortega-Heinly N, Rogers J, Yin G, Hallam TJ, Yam A, Bedard K, Begley R, Cohen CA, Badger CV, Abbasi SA, Dye JM, McMillan B, Wallach M, Bricker TL, Joshi A, Boon ACM, Pokhrel S, Kraemer BR, Lee L, Kargotich S, Agochiya M, John TS, Mochly-Rosen D. Front Immunol 13 899617 (2022)
  103. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Zhang YN, Paynter J, Sou C, Fourfouris T, Wang Y, Abraham C, Ngo T, Zhang Y, He L, Zhu J. Sci Adv 7 eabj3107 (2021)
  104. Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2. Farrell AG, Dadonaite B, Greaney AJ, Eguia R, Loes AN, Franko NM, Logue J, Carreño JM, Abbad A, Chu HY, Matreyek KA, Bloom JD. Viruses 14 2061 (2022)
  105. Editorial The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic? Al-Tawfiq JA, Hoang VT, Le Bui N, Chu DT, Memish ZA. J Epidemiol Glob Health 12 143-146 (2022)
  106. The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. Moulana A, Dupic T, Phillips AM, Chang J, Roffler AA, Greaney AJ, Starr TN, Bloom JD, Desai MM. Elife 12 e83442 (2023)
  107. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J, Zheng J, Tai W, Verma AK, Zhang X, Geng Q, Wang G, Guan X, Malisheni MM, Odle AE, Zhang W, Li F, Perlman S, Du L. J Virol 96 e0011822 (2022)
  108. Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study. Horton DB, Barrett ES, Roy J, Gennaro ML, Andrews T, Greenberg P, Bruiners N, Datta P, Ukey R, Velusamy SK, Fine D, Honnen WJ, Yin YS, Pinter A, Brooks A, Tischfield J, Hussain S, Jagpal S, Swaminathan S, Parmar V, Reilly N, Gaur S, Panettieri RA, Carson JL, Blaser MJ. J Infect Dis 224 1345-1356 (2021)
  109. Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. Paniskaki K, Anft M, Meister TL, Marheinecke C, Pfaender S, Skrzypczyk S, Seibert FS, Thieme CJ, Konik MJ, Dolff S, Anastasiou O, Holzer B, Dittmer U, Queren C, Fricke L, Rohn H, Westhoff TH, Witzke O, Stervbo U, Roch T, Babel N. Front Immunol 13 816220 (2022)
  110. Optimizing COVID-19 vaccination programs during vaccine shortages. Liu K, Lou Y. Infect Dis Model 7 286-298 (2022)
  111. SARS-CoV-2 and its beta variant of concern infect human conjunctival epithelial cells and induce differential antiviral innate immune response. Singh S, Garcia G, Shah R, Kramerov AA, Wright RE, Spektor TM, Ljubimov AV, Arumugaswami V, Kumar A. Ocul Surf 23 184-194 (2022)
  112. Letter Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209. Ju B, Zheng Q, Guo H, Fan Q, Li T, Song S, Sun H, Shen S, Zhou X, Xue W, Cui L, Zhou B, Li S, Xia N, Zhang Z. Cell Res 32 491-494 (2022)
  113. Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. Zhou W, Xu C, Wang P, Anashkina AA, Jiang Q. Brief Bioinform 23 bbab375 (2022)
  114. MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern. Wang J, Yin XG, Wen Y, Lu J, Zhang RY, Zhou SH, Liao CM, Wei HW, Guo J. J Med Chem 65 3563-3574 (2022)
  115. Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera. Yahalom-Ronen Y, Erez N, Fisher M, Tamir H, Politi B, Achdout H, Melamed S, Glinert I, Weiss S, Cohen-Gihon I, Israeli O, Izak M, Mandelboim M, Caraco Y, Madar-Balakirski N, Mechaly A, Shinar E, Zichel R, Cohen D, Beth-Din A, Zvi A, Marcus H, Israely T, Paran N. Vaccines (Basel) 10 291 (2022)
  116. Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. Sun C, Kang YF, Liu YT, Kong XW, Xu HQ, Xiong D, Xie C, Liu YH, Peng S, Feng GK, Liu Z, Zeng MS. Signal Transduct Target Ther 7 42 (2022)
  117. RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. Pan X, Shi J, Hu X, Wu Y, Zeng L, Yao Y, Shang W, Liu K, Gao G, Guo W, Peng Y, Chen S, Gao X, Peng C, Rao J, Zhao J, Gong C, Zhou H, Lu Y, Wang Z, Hu X, Cong W, Fang L, Yan Y, Zhang J, Xiong H, Yi J, Yuan Z, Zhou P, Shan C, Xiao G. Cell Discov 7 82 (2021)
  118. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. Wang J, Wen Y, Zhou SH, Zhang HW, Peng XQ, Zhang RY, Yin XG, Qiu H, Gong R, Yang GF, Guo J. J Med Chem 65 2558-2570 (2022)
  119. Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification. Yeung PS, Wang H, Sibai M, Solis D, Yamamoto F, Iwai N, Jiang B, Hammond N, Truong B, Bihon S, Santos S, Mar M, Mai C, Mfuh KO, Miller JA, Huang C, Sahoo MK, Zehnder JL, Pinsky BA. J Clin Microbiol 60 e0017822 (2022)
  120. Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. Troyano-Hernáez P, Reinosa R, Holguín Á. Int J Mol Sci 23 6394 (2022)
  121. Mutations of Omicron Variant at the Interface of the Receptor Domain Motif and Human Angiotensin-Converting Enzyme-2. Adhikari P, Jawad B, Podgornik R, Ching WY. Int J Mol Sci 23 2870 (2022)
  122. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. Dijokaite-Guraliuc A, Das R, Zhou D, Ginn HM, Liu C, Duyvesteyn HME, Huo J, Nutalai R, Supasa P, Selvaraj M, de Silva TI, Plowright M, Newman TAH, Hornsby H, Mentzer AJ, Skelly D, Ritter TG, Temperton N, Klenerman P, Barnes E, Dunachie SJ, OPTIC consortium, Roemer C, Peacock TP, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell Rep 42 112271 (2023)
  123. The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico. Zárate S, Taboada B, Muñoz-Medina JE, Iša P, Sanchez-Flores A, Boukadida C, Herrera-Estrella A, Selem Mojica N, Rosales-Rivera M, Gómez-Gil B, Salas-Lais AG, Santacruz-Tinoco CE, Montoya-Fuentes H, Alvarado-Yaah JE, Molina-Salinas GM, Espinoza-Ayala GE, Enciso-Moreno JA, Gutiérrez-Ríos RM, Loza A, Moreno-Contreras J, García-López R, Rivera-Gutierrez X, Comas-García A, Wong-Chew RM, Jiménez-Corona ME, Del Angel RM, Vazquez-Perez JA, Matías-Florentino M, Pérez-García M, Ávila-Ríos S, Castelán-Sánchez HG, Delaye L, Martínez-Castilla LP, Escalera-Zamudio M, López S, Arias CF. Microbiol Spectr 10 e0224021 (2022)
  124. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. Brinkkemper M, Brouwer PJM, Maisonnasse P, Grobben M, Caniels TG, Poniman M, Burger JA, Bontjer I, Oomen M, Bouhuijs JH, van der Linden CA, Villaudy J, van der Velden YU, Sliepen K, van Gils MJ, Le Grand R, Sanders RW. NPJ Vaccines 6 146 (2021)
  125. Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. Chen R, Zhang X, Yuan Y, Deng X, Wu B, Xi Z, Wang G, Lin Y, Li R, Wang X, Zou F, Liang L, Yan H, Liang C, Li Y, Wu S, Deng J, Zhou M, Zhang X, Li C, Bu X, Peng Y, Ke C, Deng K, He X, Zhang Y, Zhang Z, Pan T, Zhang H. Adv Sci (Weinh) 9 e2105378 (2022)
  126. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy. Ragonnet-Cronin M, Nutalai R, Huo J, Dijokaite-Guraliuc A, Das R, Tuekprakhon A, Supasa P, Liu C, Selvaraj M, Groves N, Hartman H, Ellaby N, Mark Sutton J, Bahar MW, Zhou D, Fry E, Ren J, Brown C, Klenerman P, Dunachie SJ, Mongkolsapaya J, Hopkins S, Chand M, Stuart DI, Screaton GR, Rokadiya S. Nat Commun 14 3334 (2023)
  127. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice. Song S, Zhou B, Cheng L, Liu W, Fan Q, Ge X, Peng H, Fu YX, Ju B, Zhang Z. Virol J 19 2 (2022)
  128. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern. Cohen H, Rotem S, Elia U, Bilinsky G, Levy I, Chitlaru T, Bar-Haim E. Viruses 14 347 (2022)
  129. Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China. Li Q, Liu X, Li L, Hu X, Cui G, Sun R, Zhang D, Li J, Li Y, Zhang Y, Shen S, He P, Li S, Liu Y, Yu Z, Ren Z. Front Med (Lausanne) 9 944909 (2022)
  130. Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. De Santis M, Motta F, Isailovic N, Clementi M, Criscuolo E, Clementi N, Tonutti A, Rodolfi S, Barone E, Colapietro F, Ceribelli A, Vecellio M, Luciano N, Guidelli G, Caprioli M, Rezk C, Canziani L, Azzolini E, Germagnoli L, Mancini N, Lleo A, Selmi C. Vaccines (Basel) 10 801 (2022)
  131. Emergence and Spread of the SARS-CoV-2 Variant of Concern Delta across Different Brazilian Regions. Arantes I, Gomes Naveca F, Gräf T, COVID-19 Fiocruz Genomic Surveillance Network,, Miyajima F, Faoro H, Luz Wallau G, Delatorre E, Reis Appolinario L, Cavalcante Pereira E, Venas TMM, Sampaio Rocha A, Serrano Lopes R, Mendonça Siqueira M, Bello G, Cristina Resende P. Microbiol Spectr 10 e0264121 (2022)
  132. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. Touret F, Giraud E, Bourret J, Donati F, Tran-Rajau J, Chiaravalli J, Lemoine F, Agou F, Simon-Lorière E, van der Werf S, de Lamballerie X. iScience 26 106413 (2023)
  133. High diversity in Delta variant across countries revealed by genome-wide analysis of SARS-CoV-2 beyond the Spike protein. Suratekar R, Ghosh P, Niesen MJM, Donadio G, Anand P, Soundararajan V, Venkatakrishnan AJ. Mol Syst Biol 18 e10673 (2022)
  134. Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. Wing PAC, Prange-Barczynska M, Cross A, Crotta S, Orbegozo Rubio C, Cheng X, Harris JM, Zhuang X, Johnson RL, Ryan KA, Hall Y, Carroll MW, Issa F, Balfe P, Wack A, Bishop T, Salguero FJ, McKeating JA. PLoS Pathog 18 e1010807 (2022)
  135. Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. Storti P, Marchica V, Vescovini R, Franceschi V, Russo L, Notarfranchi L, Raimondi V, Toscani D, Burroughs Garcia J, Costa F, Dalla Palma B, Iannozzi NT, Sammarelli G, Donofrio G, Giuliani N. Oncoimmunology 11 2120275 (2022)
  136. Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. Cantoni D, Mayora-Neto M, Nadesalingam A, Wells DA, Carnell GW, Ohlendorf L, Ferrari M, Palmer P, Chan ACY, Smith P, Bentley EM, Einhauser S, Wagner R, Page M, Raddi G, Baxendale H, Castillo-Olivares J, Heeney J, Temperton N. Front Immunol 13 773982 (2022)
  137. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients. Benning L, Klein K, Morath C, Bartenschlager M, Kim H, Buylaert M, Reineke M, Töllner M, Nusshag C, Kälble F, Reichel P, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Schaier M, Speer C. Front Immunol 13 840136 (2022)
  138. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Hu J, Wei XY, Xiang J, Peng P, Xu FL, Wu K, Luo FY, Jin AS, Fang L, Liu BZ, Wang K, Tang N, Huang AL. Genes Dis 9 1290-1300 (2022)
  139. SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Wang R, Zhang Q, Zhang R, Aw ZQ, Chen P, Wong YH, Hong J, Ju B, Shi X, Ding Q, Zhang Z, Chu JJH, Zhang L. Front Immunol 13 854952 (2022)
  140. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail. Addetia A, Park YJ, Starr T, Greaney AJ, Sprouse KR, Bowen JE, Tiles SW, Van Voorhis WC, Bloom JD, Corti D, Walls AC, Veesler D. Cell Rep 42 112621 (2023)
  141. A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells. Appelberg S, Ahlén G, Yan J, Nikouyan N, Weber S, Larsson O, Höglund U, Aleman S, Weber F, Perlhamre E, Apro J, Gidlund EK, Tuvesson O, Salati S, Cadossi M, Tegel H, Hober S, Frelin L, Mirazimi A, Sällberg M. EMBO Mol Med 14 e15821 (2022)
  142. Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD. Ma H, Guo Y, Tang H, Tseng CK, Wang L, Zong H, Wang Z, He Y, Chang Y, Wang S, Huang H, Ke Y, Yuan Y, Wu M, Zhang Y, Drelich A, Kempaiah KR, Peng BH, Wang A, Yang K, Yin H, Liu J, Yue Y, Xu W, Zhu S, Ji T, Zhang X, Wang Z, Li G, Liu G, Song J, Mu L, Xiang Z, Song Z, Chen H, Bian Y, Zhang B, Chen H, Zhang J, Liao Y, Zhang L, Yang L, Chen Y, Gilly J, Xiao X, Han L, Jiang H, Xie Y, Zhou Q, Zhu J. Cell Discov 8 16 (2022)
  143. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. Celik I, Khan A, Dwivany FM, Fatimawali, Wei DQ, Tallei TE. Mol Divers 26 3309-3324 (2022)
  144. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19. Zhang JW, Xiong Y, Wang F, Zhang FM, Yang X, Lin GQ, Tian P, Ge G, Gao D. Eur J Med Chem 228 114030 (2022)
  145. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. Zhang N, Ji Q, Liu Z, Tang K, Xie Y, Li K, Zhou J, Li S, Shang H, Shi Z, Zheng T, Yao J, Lu L, Yuan S, Jiang S. Viruses 14 501 (2022)
  146. From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? Pavan M, Bassani D, Sturlese M, Moro S. J Enzyme Inhib Med Chem 37 1704-1714 (2022)
  147. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. Sieber J, Mayer M, Schmidthaler K, Kopanja S, Camp JV, Popovitsch A, Dwivedi V, Hoz J, Schoof A, Weseslindtner L, Szépfalusi Z, Stiasny K, Aberle JH. Front Immunol 13 882456 (2022)
  148. Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China. Han X, Yu X, Han Y, Fang Q, Shen C, Liu H, Wang P, Wang Y, Li X. Infect Drug Resist 15 2091-2100 (2022)
  149. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. Greaney AJ, Eguia RT, Starr TN, Khan K, Franko N, Logue JK, Lord SM, Speake C, Chu HY, Sigal A, Bloom JD. PLoS Pathog 18 e1010592 (2022)
  150. Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. Liu Q, Xiong Q, Mei F, Ma C, Zhang Z, Hu B, Xu J, Jiang Y, Zhan F, Zhou S, Tao L, Chen X, Guo M, Wang X, Fang Y, Shen S, Liu Y, Liu F, Zhou L, Xu K, Ke C, Deng F, Cai K, Yan H, Chen Y, Lan K. Innovation (Camb) 3 100181 (2022)
  151. Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine. Lam JH, Shivhare D, Chia TW, Chew SL, Sinsinbar G, Aw TY, Wong S, Venkataraman S, Lim FWI, Vandepapeliere P, Nallani M. ACS Nano 16 16757-16775 (2022)
  152. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination. Chi X, Guo Y, Zhang G, Sun H, Zhang J, Li M, Chen Z, Han J, Zhang Y, Zhang X, Fan P, Zhang Z, Wang B, Zai X, Han X, Hao M, Fang T, Xu J, Wu S, Chen Y, Fang Y, Dong Y, Sun B, Zhang J, Li J, Zhao G, Yu C, Zhou Q, Chen W. Signal Transduct Target Ther 7 139 (2022)
  153. Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations. Verkhivker G, Agajanian S, Kassab R, Krishnan K. Int J Mol Sci 23 4376 (2022)
  154. Letter Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. Cheng L, Song S, Fan Q, Shen S, Wang H, Zhou B, Ge X, Ju B, Zhang Z. Cell Discov 7 112 (2021)
  155. Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. Lin HT, Chen CC, Chiao DJ, Chang TY, Chen XA, Young JJ, Kuo SC. Int J Biol Macromol 193 1885-1897 (2021)
  156. Rational identification of small molecules derived from 9,10-dihydrophenanthrene as potential inhibitors of 3CLpro enzyme for COVID-19 therapy: a computer-aided drug design approach. Daoui O, Elkhattabi S, Chtita S. Struct Chem 33 1667-1690 (2022)
  157. A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World. Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. Aging Dis 13 927-942 (2022)
  158. COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study. Dick DW, Childs L, Feng Z, Li J, Röst G, Buckeridge DL, Ogden NH, Heffernan JM. Vaccines (Basel) 10 17 (2021)
  159. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study. Herzberg J, Fischer B, Becher H, Becker AK, Honarpisheh H, Guraya SY, Strate T, Knabbe C. Front Immunol 13 896151 (2022)
  160. Changing Features of COVID-19: Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2) and Alpha (B.1.1.7) Variants in Southern Italy. Loconsole D, Centrone F, Morcavallo C, Campanella S, Accogli M, Sallustio A, Peccarisi D, Stufano A, Lovreglio P, Chironna M. Vaccines (Basel) 9 1354 (2021)
  161. Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses. Brinkkemper M, Veth TS, Brouwer PJM, Turner H, Poniman M, Burger JA, Bouhuijs JH, Olijhoek W, Bontjer I, Snitselaar JL, Caniels TG, van der Linden CA, Ravichandran R, Villaudy J, van der Velden YU, Sliepen K, van Gils MJ, Ward AB, King NP, Heck AJR, Sanders RW. iScience 25 105649 (2022)
  162. Conserved Pattern and Potential Role of Recurrent Deletions in SARS-CoV-2 Evolution. Weng S, Zhou H, Ji C, Li L, Han N, Yang R, Shang J, Wu A. Microbiol Spectr 10 e0219121 (2022)
  163. Dominance of Three Sublineages of the SARS-CoV-2 Delta Variant in Mexico. Taboada B, Zárate S, García-López R, Muñoz-Medina JE, Sanchez-Flores A, Herrera-Estrella A, Boukadida C, Gómez-Gil B, Selem Mojica N, Rosales-Rivera M, Salas-Lais AG, Gutiérrez-Ríos RM, Loza A, Rivera-Gutierrez X, Vazquez-Perez JA, Matías-Florentino M, Pérez-García M, Ávila-Ríos S, Hurtado JM, Herrera-Nájera CI, Núñez-Contreras JJ, Sarquiz-Martínez B, García-Arias VE, Santiago-Mauricio MG, Martínez-Miguel B, Enciso-Ibarra J, Cháidez-Quiróz C, Iša P, Wong-Chew RM, Jiménez-Corona ME, López S, Arias CF. Viruses 14 1165 (2022)
  164. In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants. Tran HTT, Gigl M, Le NPK, Dawid C, Lamy E. Pharmaceuticals (Basel) 14 1055 (2021)
  165. Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain. Pitsillou E, Liang JJ, Beh RC, Hung A, Karagiannis TC. Comput Biol Med 149 106035 (2022)
  166. Pathogen evolution during vaccination campaigns. Day T, Kennedy DA, Read AF, Gandon S. PLoS Biol 20 e3001804 (2022)
  167. Statistical and agent-based modelling of the transmissibility of different SARS-CoV-2 variants in England and impact of different interventions. Panovska-Griffiths J, Swallow B, Hinch R, Cohen J, Rosenfeld K, Stuart RM, Ferretti L, Di Lauro F, Wymant C, Izzo A, Waites W, Viner R, Bonell C, Fraser C, Klein D, Kerr CC, COVID-19 Genomics UK (COG-UK) Consortium. Philos Trans A Math Phys Eng Sci 380 20210315 (2022)
  168. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. Li G, Zhou Z, Du P, Yu M, Li N, Xiong X, Huang H, Liu Z, Dai Q, Zhu J, Guo C, Wu S, Baptista-Hon DT, Miao M, Ming LW, Wu Y, Zeng F, Zhang CL, Zhang ED, Song H, Liu J, Lau JY, Xiang AP, Zhang K. Precis Clin Med 4 149-154 (2021)
  169. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. Amanat F, Strohmeier S, Meade PS, Dambrauskas N, Mühlemann B, Smith DJ, Vigdorovich V, Sather DN, Coughlan L, Krammer F. PLoS Biol 19 e3001384 (2021)
  170. A Routine Sanger Sequencing Target Specific Mutation Assay for SARS-CoV-2 Variants of Concern and Interest. Lee SH. Viruses 13 2386 (2021)
  171. Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. Duerr R, Dimartino D, Marier C, Zappile P, Levine S, Francois F, Iturrate E, Wang G, Dittmann M, Lighter J, Elbel B, Troxel AB, Goldfeld KS, Heguy A. EBioMedicine 82 104141 (2022)
  172. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Li X, Wang L, Liu J, Fang E, Liu X, Peng Q, Zhang Z, Li M, Liu X, Wu X, Zhao D, Yang L, Li J, Cao S, Huang Y, Shi L, Xu H, Wang Y, Suo Y, Yue G, Nie J, Huang W, Li W, Li Y. Emerg Microbes Infect 11 1890-1899 (2022)
  173. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. Lien CE, Kuo TY, Lin YJ, Lian WC, Lin MY, Liu LT, Cheng J, Chou YC, Chen C. Clin Infect Dis 74 1899-1905 (2022)
  174. Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. Xiong D, Zhao X, Luo S, Cong Y, Zhang JZH, Duan L. J Phys Chem Lett 13 6064-6073 (2022)
  175. Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type. Dingemans J, van der Veer BMJW, Gorgels KMF, Hackert V, den Heijer CDJ, Hoebe CJPA, Savelkoul PHM, van Alphen LB. Front Microbiol 13 1027271 (2022)
  176. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. Torchia JA, Tavares AH, Carstensen LS, Chen DY, Huang J, Xiao T, Mukherjee S, Reeves PM, Tu H, Sluder AE, Chen B, Kotton DN, Bowen RA, Saeed M, Poznansky MC, Freeman GJ. Sci Adv 8 eabq6527 (2022)
  177. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. da Silva ES, Kohnen M, Gilson G, Staub T, Arendt V, Hilger C, Servais JY, Charpentier E, Domingues O, Snoeck CJ, Ollert M, Seguin-Devaux C, Perez-Bercoff D. Int J Mol Sci 23 7675 (2022)
  178. RCSB Protein Data Bank resources for structure-facilitated design of mRNA vaccines for existing and emerging viral pathogens. Goodsell DS, Burley SK. Structure 30 55-68.e2 (2022)
  179. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. Moyo-Gwete T, Madzivhandila M, Mkhize NN, Kgagudi P, Ayres F, Lambson BE, Manamela NP, Richardson SI, Makhado Z, van der Mescht MA, de Beer Z, de Villiers TR, Burgers WA, Ntusi NAB, Rossouw T, Ueckermann V, Boswell MT, Moore PL. J Virol 96 e0055822 (2022)
  180. The ORF8 Protein of SARS-CoV-2 Modulates the Spike Protein and Its Implications in Viral Transmission. Chou JM, Tsai JL, Hung JN, Chen IH, Chen ST, Tsai MH. Front Microbiol 13 883597 (2022)
  181. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain. Wu J, Nie J, Zhang L, Song H, An Y, Liang Z, Yang J, Ding R, Liu S, Li Q, Li T, Cui Z, Zhang M, He P, Wang Y, Qu X, Hu Z, Wang Q, Huang W. Signal Transduct Target Ther 7 18 (2022)
  182. The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ T cell responses. Jung S, Jung JH, Noh JY, Kim WJ, Yoon SY, Jung J, Kim ES, Kim HB, Cheong HJ, Kim WJ, Park SH, Song KH, Song JY, Shin EC. Cell Rep 40 111138 (2022)
  183. A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. van der Velden YU, Grobben M, Caniels TG, Burger JA, Poniman M, Oomen M, Rijnstra ES, Tejjani K, Guerra D, Kempers R, Stegmann T, van Gils MJ, Sanders RW. Sci Rep 12 3884 (2022)
  184. Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617. Fan LQ, Hu XY, Chen YY, Peng XL, Fu YH, Zheng YP, Yu JM, He JS. Front Microbiol 12 750725 (2021)
  185. ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Seow J, Graham C, Hallett SR, Lechmere T, Maguire TJA, Huettner I, Cox D, Khan H, Pickering S, Roberts R, Waters A, Ward CC, Mant C, Pitcher MJ, Spencer J, Fox J, Malim MH, Doores KJ. Cell Rep 39 110757 (2022)
  186. Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. Hu YF, Hu JC, Gong HR, Danchin A, Sun R, Chu H, Hung IF, Yuen KY, To KK, Zhang BZ, Yau T, Huang JD. Front Immunol 13 861050 (2022)
  187. Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. Ching WY, Adhikari P, Jawad B, Podgornik R. Int J Mol Sci 23 10091 (2022)
  188. Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. Arora P, Sidarovich A, Graichen L, Hörnich B, Hahn A, Hoffmann M, Pöhlmann S. PLoS One 17 e0265453 (2022)
  189. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. Saunders N, Planas D, Bolland WH, Rodriguez C, Fourati S, Buchrieser J, Planchais C, Prot M, Staropoli I, Guivel-Benhassine F, Porrot F, Veyer D, Péré H, Robillard N, Saliba M, Baidaliuk A, Seve A, Hocqueloux L, Prazuck T, Rey FA, Mouquet H, Simon-Lorière E, Bruel T, Pawlotsky JM, Schwartz O. EBioMedicine 77 103934 (2022)
  190. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Halfmann PJ, Kuroda M, Armbrust T, Accola M, Valdez R, Kowalski-Dobson T, Rehrauer W, Gordon A, Kawaoka Y. Cell Rep 38 110394 (2022)
  191. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Odak I, Schultze-Florey CR, Hammerschmidt SI, Ritter C, Willenzon S, Friedrichsen M, Ravens I, Sikora R, Bayir LM, Gutierrez Jauregui R, Bernhardt G, Stankov MV, Cossmann A, Hansen G, Krey T, Cornberg M, Koenecke C, Behrens GMN, Bošnjak B, Förster R. Front Immunol 13 863039 (2022)
  192. Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction. Santra D, Maiti S. Struct Chem 33 1755-1769 (2022)
  193. Population immunity predicts evolutionary trajectories of SARS-CoV-2. Meijers M, Ruchnewitz D, Eberhardt J, Łuksza M, Lässig M. Cell 186 5151-5164.e13 (2023)
  194. Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae. Deng Y, Li J, Sun C, Chi H, Luo D, Wang R, Qiu H, Zhang Y, Wu M, Zhang X, Huang X, Xie L, Qin C. Adv Mater 34 e2200443 (2022)
  195. Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). Wu X, Wang Y, Cheng L, Ni F, Zhu L, Ma S, Huang B, Ji M, Hu H, Li Y, Xu S, Shi H, Zhang D, Liu L, Nawaz W, Hu Q, Ye S, Liu Y, Wu Z. Front Immunol 13 865401 (2022)
  196. Letter Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. Pan T, Hu Z, Hu F, Zhang Y, Liu B, Ke C, She Q, He X, Tang X, Zhang H. Cell Mol Immunol 18 2560-2562 (2021)
  197. An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry. Lin X, Guo L, Lin S, Chen Z, Yang F, Yang J, Wang L, Wen A, Duan Y, Zhang X, Dai Y, Yin K, Yuan X, Yu C, He B, Cao Y, Dong H, Li J, Zhao Q, Lu G. Emerg Microbes Infect 11 1920-1935 (2022)
  198. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults. Um J, Choi YY, Kim G, Kim MK, Lee KS, Sung HK, Kim BC, Lee YK, Jang HC, Bang JH, Chung KH, Oh MD, Park JS, Jeon J. J Korean Med Sci 37 e70 (2022)
  199. Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. Komissarov AA, Dolzhikova IV, Efimov GA, Logunov DY, Mityaeva O, Molodtsov IA, Naigovzina NB, Peshkova IO, Shcheblyakov DV, Volchkov P, Gintsburg AL, Vasilieva E. J Immunol 208 1139-1145 (2022)
  200. Comparing the evolutionary dynamics of predominant SARS-CoV-2 virus lineages co-circulating in Mexico. Castelán-Sánchez HG, Delaye L, Inward RPD, Dellicour S, Gutierrez B, Martinez de la Vina N, Boukadida C, Pybus OG, de Anda Jáuregui G, Guzmán P, Flores-Garrido M, Fontanelli Ó, Hernández Rosales M, Meneses A, Olmedo-Alvarez G, Herrera-Estrella AH, Sánchez-Flores A, Muñoz-Medina JE, Comas-García A, Gómez-Gil B, Zárate S, Taboada B, López S, Arias CF, Kraemer MUG, Lazcano A, Escalera Zamudio M. Elife 12 e82069 (2023)
  201. Delta Variant with P681R Critical Mutation Revealed by Ultra-Large Atomic-Scale Ab Initio Simulation: Implications for the Fundamentals of Biomolecular Interactions. Adhikari P, Jawad B, Rao P, Podgornik R, Ching WY. Viruses 14 465 (2022)
  202. Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 pandemic and subsequent 1-year global expansion. Chen Y, Li S, Wu W, Geng S, Mao M. J Med Virol 94 2035-2049 (2022)
  203. Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron. Zhou B, Cheng L, Song S, Guo H, Shen S, Wang H, Ge X, Liu L, Ju B, Zhang Z. Virol J 19 96 (2022)
  204. Letter Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients. Benning L, Morath C, Bartenschlager M, Reineke M, Töllner M, Nusshag C, Kälble F, Reichel P, Schaier M, Schnitzler P, Zeier M, Süsal C, Bartenschlager R, Speer C. Kidney Int 101 639-642 (2022)
  205. Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. Amano M, Otsu S, Maeda K, Uemura Y, Shimizu Y, Omata K, Matsuoka M, Shimada S, Mitsuya H. Sci Rep 12 13524 (2022)
  206. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern. Valdovino-Navarro BJ, Dueñas S, Flores-Acosta GI, Gasperin-Bulbarela J, Bernaldez-Sarabia J, Cabanillas-Bernal O, Cervantes-Luevano KE, Licea-Navarro AF. Int J Mol Sci 23 12267 (2022)
  207. Resistance of SARS-CoV-2 beta and gamma variants to plasma collected from Canadian blood donors during the spring of 2020. Drews SJ, Abe KT, Hu Q, Samson R, Gingras AC, Colwill K, Rathod B, Wang J, Fazel-Zarandi M, Yi QL, Robinson A, Wood H, Tuite A, Fisman D, Evans DH, Lin YJ, O'Brien SF. Transfusion 62 37-43 (2022)
  208. Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model. Tada T, Peng JY, Dcosta BM, Landau NR. JCI Insight 8 e167306 (2023)
  209. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants. Kim D, Keskinocak P, Pekgün P, Yildirim İ. Sci Rep 12 7493 (2022)
  210. Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. Yu CY, Wong SY, Liew NWC, Joseph N, Zakaria Z, Nurulfiza I, Soe HJ, Kairon R, Amin-Nordin S, Chee HY. Front Med (Lausanne) 9 1001022 (2022)
  211. Oscillatoria limnetica Mediated Green Synthesis of Iron Oxide (Fe2O3) Nanoparticles and Their Diverse In Vitro Bioactivities. Haris M, Fatima N, Iqbal J, Chalgham W, Mumtaz AS, El-Sheikh MA, Tavafoghi M. Molecules 28 2091 (2023)
  212. A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. Gao F, Huang J, Li T, Hu C, Shen M, Mu S, Luo F, Song S, Hao Y, Wang W, Han X, Qian C, Wang Y, Wu R, Li L, Li S, Jin A. Front Immunol 12 789905 (2021)
  213. ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants. Wang B, Zhao J, Liu S, Feng J, Luo Y, He X, Wang Y, Ge F, Wang J, Ye B, Huang W, Bo X, Wang Y, Xi JJ. Emerg Microbes Infect 11 1488-1499 (2022)
  214. Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies. Guo H, Jiang J, Shen S, Ge X, Fan Q, Zhou B, Cheng L, Ju B, Zhang Z. iScience 26 106283 (2023)
  215. Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. Hwa SH, Snyman J, Bernstein M, Ganga Y, Cele S, Muema D, Tan CW, Khan K, Karim F, Hanekom W, Bernstein L, Kaufmann SHE, Wang LF, Ndung'u T, Sigal A, COMMIT-KZN Team. J Infect Dis 227 211-220 (2023)
  216. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. Dubé C, Paris-Robidas S, Andreani G, Gutzeit C, D'Aoust MA, Ward BJ, Trépanier S. Vaccine 40 4017-4025 (2022)
  217. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants. Fryer HA, Hartley GE, Edwards ESJ, Varese N, Boo I, Bornheimer SJ, Hogarth PM, Drummer HE, O'Hehir RE, van Zelm MC. J Clin Immunol 43 1506-1518 (2023)
  218. Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. Toomer G, Burns W, Garcia L, Henry G, Biancofiori A, George A, Duffy C, Chu J, Sides M, Muñoz M, Garcia K, Nikolai-Yogerst A, Peng X, Westfall L, Baker R. Viruses 14 2584 (2022)
  219. Duration of Humoral Immunity and Cross-Neutralizing Activity Against the Alpha, Beta, and Delta Variants After Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Prospective Cohort Study. Noh JY, Yang JS, Hwang SY, Hyun H, Seong H, Gu Yoon J, Yoon SY, Cheong HJ, Kim WJ, Park WJ, Kim JW, Lee JY, Song JY. J Infect Dis 226 975-978 (2022)
  220. Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination. Johnson SA, Phillips E, Adele S, Longet S, Malone T, Mason C, Stafford L, Jamsen A, Gardiner S, Deeks A, Neo J, Blurton EJ, White J, Ali M, Kronsteiner B, Wilson JD, Skelly DT, Jeffery K, Conlon CP, Goulder P, Consortium P, Carroll M, Barnes E, Klenerman P, Dunachie SJ. Clin Exp Immunol 212 249-261 (2023)
  221. Finger stick blood test to assess postvaccination SARS-CoV-2 neutralizing antibody response against variants. Lim SM, Cheng HL, Jia H, Kongsuphol P, D/O Shunmuganathan B, Chen MW, Ng SY, Gao X, Turaga SP, Heussler SP, Somani J, Sengupta S, Tay DMY, McBee ME, Young BE, MacAry PA, Sikes HD, Preiser PR. Bioeng Transl Med 7 e10293 (2022)
  222. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Graninger M, Camp JV, Aberle SW, Traugott MT, Hoepler W, Puchhammer-Stöckl E, Weseslindtner L, Zoufaly A, Aberle JH, Stiasny K. Front Immunol 13 888794 (2022)
  223. Home Quarantine: A Double-Edged Sword During COVID-19 Pandemic for Hypertensive Disorders of Pregnancy and the Related Complications. Cai QY, Yang Y, Wang YH, Cui HL, Wu XP, Liao KM, Luo X, Liu TH. Diabetes Metab Syndr Obes 15 2405-2415 (2022)
  224. Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization. Guo H, Fan Q, Song S, Shen S, Zhou B, Wang H, Cheng L, Ge X, Ju B, Zhang Z. J Clin Virol 150-151 105162 (2022)
  225. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. Nham E, Ko JH, Song KH, Choi JY, Kim ES, Kim HJ, Kim B, Lim HY, Kim KC, Jang HC, Lee KH, Song YG, Baek YJ, Ahn JY, Choi JY, Kim YC, Park YS, Choi WS, Bae S, Kim SH, Kang ES, Jeong HW, Kim SW, Kwon KT, Kim SS, Peck KR. Front Immunol 13 968105 (2022)
  226. Structural evolution of Delta lineage of SARS-CoV-2. Gomari MM, Tarighi P, Choupani E, Abkhiz S, Mohamadzadeh M, Rostami N, Sadroddiny E, Baammi S, Uversky VN, Dokholyan NV. Int J Biol Macromol 226 1116-1140 (2023)
  227. Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2. Gong SY, Ding S, Benlarbi M, Chen Y, Vézina D, Marchitto L, Beaudoin-Bussières G, Goyette G, Bourassa C, Bo Y, Medjahed H, Levade I, Pazgier M, Côté M, Richard J, Prévost J, Finzi A. Viruses 14 2178 (2022)
  228. Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Zhao J, Zhu J, Huang C, Zhu X, Zhu Z, Wu Q, Yuan R. Front Immunol 13 1035151 (2022)
  229. A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. Eslami S, Glassy MC, Ghafouri-Fard S. Gene 813 146113 (2022)
  230. Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. Li T, Cui Z, Jia Y, Liang Z, Nie J, Zhang L, Wang M, Li Q, Wu J, Xu N, Liu S, Li X, An Y, Han P, Zhang M, Li Y, Qu X, Wang Q, Huang W, Wang Y. J Med Virol 94 2108-2125 (2022)
  231. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Kaplonek P, Cizmeci D, Kwatra G, Izu A, Lee JS, Bertera HL, Fischinger S, Mann C, Amanat F, Wang W, Koen AL, Fairlie L, Cutland CL, Ahmed K, Dheda K, Barnabas SL, Bhorat QE, Briner C, Krammer F, Saphire EO, Gilbert SC, Lambe T, Pollard AJ, Nunes M, Wuhrer M, Lauffenburger DA, Madhi SA, Alter G. Nat Immunol 24 1161-1172 (2023)
  232. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses. Li Q, Zhang L, Liang Z, Wang N, Liu S, Li T, Yu Y, Cui Q, Wu X, Nie J, Wu J, Cui Z, Lu Q, Wang X, Huang W, Wang Y. Signal Transduct Target Ther 7 256 (2022)
  233. Crucial control measures to contain China's first Delta variant outbreak. Luo L, Yang Z, Liang J, Ma Y, Wang H, Hon C, Jiang M, Lin Z, Guan W, Mai Z, Li Y, Mai K, Zeng Z, Tu C, Song J, Liu B, Liu Y, He J, Li H, Li B, Dong H, Miao Y, Fan S, Fan L, Liang X, Li K, Chen C, Deng H, Yang Z, Zhong N. Natl Sci Rev 9 nwac004 (2022)
  234. Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice. Shen AR, Jin XX, Tang TT, Ding Y, Liu XT, Zhong X, Wu YD, Han XL, Zhao GY, Shen CL, Lv LL, Liu BC. Int J Nanomedicine 17 3325-3341 (2022)
  235. Letter Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS-CoV-2 vaccine. Xu X, Liao Y, Jiang G, Yao W, Duan S, Xiao K, Ding X, Zhao H, Zhang Y, Zhang A, Yang J, Che Y, Zhang J, Zhao F, Ma X, Zhao Z, Cui P, Yang X, Lin X, Cai W, Yan J, Yang Z, Qiu H, Zhang J, Huang L, Shen M, Zhao G, Yu L, Li D, Fan S, Zhang Y, Wang L, He L, Dong F, Xu W, Li H, Li Q. Clin Transl Med 12 e875 (2022)
  236. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. Roe TL, Brady T, Schuko N, Nguyen A, Beloor J, Guest JD, Aksyuk AA, Tuffy KM, Zhang T, Streicher K, Kelly EJ, Kijak GH. Microbiol Spectr e0033323 (2023)
  237. Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models. Zhang Y, Sun J, Zheng J, Li S, Rao H, Dai J, Zhang Z, Wang Y, Liu D, Chen Z, Ran W, Zhu A, Li F, Yan Q, Wang Y, Yu K, Zhang S, Wang D, Tang Y, Liu B, Cheng L, Huo J, Perlman S, Zhao J, Zhao J. Adv Sci (Weinh) 11 e2303366 (2024)
  238. Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations. Ma J, Bai H, Gong T, Mao W, Nie Y, Zhang X, Da Y, Wang X, Qin H, Zeng Q, Hu F, Qi X, Shi B, Zhang C. Immunol Lett 249 23-32 (2022)
  239. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. Lima NS, Musayev M, Johnston TS, Wagner DA, Henry AR, Wang L, Yang ES, Zhang Y, Birungi K, Black WP, O'Dell S, Schmidt SD, Moon D, Lorang CG, Zhao B, Chen M, Boswell KL, Roberts-Torres J, Davis RL, Peyton L, Narpala SR, O'Connell S, Serebryannyy L, Wang J, Schrager A, Talana CA, Shimberg G, Leung K, Shi W, Khashab R, Biber A, Zilberman T, Rhein J, Vetter S, Ahmed A, Novik L, Widge A, Gordon I, Guech M, Teng IT, Phung E, Ruckwardt TJ, Pegu A, Misasi J, Doria-Rose NA, Gaudinski M, Koup RA, Kwong PD, McDermott AB, Amit S, Schacker TW, Levy I, Mascola JR, Sullivan NJ, Schramm CA, Douek DC. Nat Commun 13 7733 (2022)
  240. Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test. Roessler J, Pich D, Albanese M, Wratil PR, Krähling V, Hellmuth JC, Scherer C, von Bergwelt-Baildon M, Becker S, Keppler OT, Brisson A, Zeidler R, Hammerschmidt W. PNAS Nexus 1 pgac045 (2022)
  241. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Drews SJ, Hu Q, Samson R, Abe KT, Rathod B, Colwill K, Gingras AC, Yi QL, O'Brien SF. Microbiol Spectr 10 e0226221 (2022)
  242. Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants. Li Y, Fan Q, Zhou B, Shen Y, Zhang Y, Cheng L, Qi F, Song S, Guo Y, Yan R, Ju B, Zhang Z. iScience 25 104431 (2022)
  243. Twelve-Month Longitudinal Serology in SARS-CoV-2 Naïve and Experienced Vaccine Recipients and Unvaccinated COVID-19-Infected Individuals. Congrave-Wilson Z, Cheng WA, Lee Y, Perez S, Turner L, Marentes Ruiz CJ, Mendieta S, Skura A, Jumarang J, Del Valle J, Kubale J, Allen EK, Thomas PG, Gordon A, Pannaraj PS. Vaccines (Basel) 10 813 (2022)
  244. A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants. Hernandez MM, Banu R, Shrestha P, Gonzalez-Reiche AS, van de Guchte A, Farrugia K, Sebra R, Mount Sinai PSP Study Group, Gitman MR, Nowak MD, Cordon-Cardo C, Simon V, van Bakel H, Sordillo EM, Luna N, Ramirez A, Castañeda SA, Patiño LH, Ballesteros N, Muñoz M, Ramírez JD, Paniz-Mondolfi AE. Microbiol Spectr 10 e0173622 (2022)
  245. A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Brandys P, Montagutelli X, Merenkova I, Barut GT, Thiel V, Schork NJ, Trüeb B, Conquet L, Deng A, Antanasijevic A, Lee HK, Valière M, Sindhu A, Singh G, Herold J. Front Immunol 13 912898 (2022)
  246. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity. Liu C, Zhou D, Dijokaite-Guraliuc A, Supasa P, Duyvesteyn HME, Ginn HM, Selvaraj M, Mentzer AJ, Das R, de Silva TI, Ritter TG, Plowright M, Newman TAH, Stafford L, Kronsteiner B, Temperton N, Lui Y, Fellermeyer M, Goulder P, Klenerman P, Dunachie SJ, Barton MI, Kutuzov MA, Dushek O, OPTIC Consortium, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell Rep Med 5 101553 (2024)
  247. Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants. Mühlemann B, Trimpert J, Walper F, Schmidt ML, Jansen J, Schroeder S, Jeworowski LM, Beheim-Schwarzbach J, Bleicker T, Niemeyer D, Richter A, Adler JM, Vidal RM, Langner C, Vladimirova D, Wilks SH, Smith DJ, Voß M, Paltzow L, Martínez Christophersen C, Rose R, Krumbholz A, Jones TC, Corman VM, Drosten C. Proc Natl Acad Sci U S A 121 e2310917121 (2024)
  248. Comparison of initial clinic characteristics of hospitalized patients in Suzhou City during the COVID-19 Omicron wave with ancestral variant wave. Gu B, Yao L, Zhu XY, Zou T, Feng YJ, Yan JY, Zhang JP, Tang PJ, Chen C. Ther Adv Respir Dis 16 17534666221110346 (2022)
  249. Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. Wang E, Chakraborty AK. PLoS Comput Biol 18 e1010563 (2022)
  250. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees. Jäger M, Sonnleitner ST, Dichtl S, Lafon E, Diem G, Walder G, Lass-Flörl C, Wilflingseder D, Posch W. Front Immunol 13 868361 (2022)
  251. Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. Yang MC, Wang CC, Tang WC, Chen KM, Chen CY, Lin HH, Hsieh YC, Wang NH, Kuo YC, Chu PT, Tung HY, Wu YC, Sun JL, Liu SY, Li WF, Lee WH, Lai JS, Chang M, Lai MT. PLoS One 18 e0283473 (2023)
  252. Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. Vellas C, Del Bello A, Gaube G, Tremeaux P, Jeanne N, Ranger N, Martin-Blondel G, Delobel P, Kamar N, Izopet J. Open Forum Infect Dis 9 ofac093 (2022)
  253. Inactivated vaccines prevent severe COVID-19 in patients infected with the Delta variant: A comparative study of the Delta and Alpha variants from China. Ye C, Lv Y, Kuang W, Yang L, Lu Y, Gu J, Ding F, Shen H, Yang Y. J Med Virol 94 3613-3624 (2022)
  254. Mutations and Phylogenetic Analyses of SARS-CoV-2 Among Imported COVID-19 From Abroad in Nanjing, China. Zhao N, Zhou N, Fan H, Ding J, Xu X, Dong X, Dong X, Xu D, Min X, Yu Y, Gong H, Mao L, He M. Front Microbiol 13 851323 (2022)
  255. Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19. Wen Y, Zhang RY, Wang J, Zhou SH, Peng XQ, Ding D, Zhang ZM, Wei HW, Guo J. J Control Release 355 238-247 (2023)
  256. Personal care formulations demonstrate virucidal efficacy against multiple SARS-CoV-2 variants of concern: Implications for hand hygiene and public health. Mukherjee S, Vincent CK, Jayasekera HW, Yekhe AS. PLOS Glob Public Health 2 e0000228 (2022)
  257. Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. Hastie KM, Yu X, Ana-Sosa-Batiz F, Zyla DS, Harkins SS, Hariharan C, Wasserman H, Zandonatti MA, Miller R, Maule E, Kim K, Valentine KM, Shresta S, Saphire EO. Cell Rep 42 112421 (2023)
  258. Case Reports Rapid repeat infection of SARS-CoV-2 by two highly distinct delta-lineage viruses. Gorzalski AJ, Boyles C, Sepcic V, Verma S, Sevinsky J, Libuit K, Van Hooser S, Pandori MW. Diagn Microbiol Infect Dis 104 115747 (2022)
  259. Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice. Shi J, Jin X, Ding Y, Liu X, Shen A, Wu Y, Peng M, Shen C. Vaccines (Basel) 9 1383 (2021)
  260. SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. Chan KC, Song Y, Xu Z, Shang C, Zhou R. Biomolecules 12 1742 (2022)
  261. SARS-CoV-2 and Its Variants: The Pandemic of Unvaccinated. Angius F, Pala G, Manzin A. Front Microbiol 12 749634 (2021)
  262. Editorial The emergence, dynamics and significance of SARS-CoV-2 variants. Colson P, Parola P, Raoult D. New Microbes New Infect 45 100962 (2022)
  263. Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review. Reynolds L, Dewey C, Asfour G, Little M. Front Public Health 11 1229716 (2023)
  264. A Reverse Transcription Recombinase-Aided Amplification Method for Rapid and Point-of-Care Detection of SARS-CoV-2, including Variants. Li F, He P, Xiong D, Lou Y, Pu Q, Zhang H, Zhang H, Yu J. Viruses 13 1875 (2021)
  265. Accurate identification of SARS-CoV-2 variant delta using graphene/CRISPR-dCas9 electrochemical biosensor. Yang B, Zeng X, Zhang J, Kong J, Fang X. Talanta 249 123687 (2022)
  266. Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. Cantoni D, Siracusano G, Mayora-Neto M, Pastori C, Fantoni T, Lytras S, Di Genova C, Hughes J, On Behalf Of The Ambulatorio Medico San Luca Villanuova Group, Lopalco L, Temperton N. Vaccines (Basel) 11 58 (2022)
  267. Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. Jacobsen H, Sitaras I, Jurgensmeyer M, Mulders MN, Goldblatt D, Feikin DR, Bar-Zeev N, Higdon MM, Knoll MD. Vaccines (Basel) 10 850 (2022)
  268. Association of Online Search Trends With Vaccination in the United States: June 2020 Through May 2021. Berning P, Huang L, Razavi AC, Boakye E, Osuji N, Stokes AC, Martin SS, Ayers JW, Blaha MJ, Dzaye O. Front Immunol 13 884211 (2022)
  269. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain. Gao X, Fan L, Zheng B, Li H, Wang J, Zhang L, Li J, Zhu F. Hum Vaccin Immunother 18 2055373 (2022)
  270. COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2. Chen WC, Hu SY, Shen CF, Chuang HY, Ker CR, Shen CJ, Cheng CM. Vaccines (Basel) 11 1425 (2023)
  271. Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. Zabaleta N, Bhatt U, Hérate C, Maisonnasse P, Sanmiguel J, Diop C, Castore S, Estelien R, Li D, Dereuddre-Bosquet N, Cavarelli M, Gallouët AS, Pascal Q, Naninck T, Kahlaoui N, Lemaitre J, Relouzat F, Ronzitti G, Thibaut HJ, Montomoli E, Wilson JM, Le Grand R, Vandenberghe LH. Mol Ther 30 2952-2967 (2022)
  272. Fast Prediction of Binding Affinities of SARS-CoV-2 Spike Protein and Its Mutants with Antibodies through Intermolecular Interaction Modeling-Based Machine Learning. Williams AH, Zhan CG. J Phys Chem B 126 5194-5206 (2022)
  273. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Ho HPT, Vo DNK, Lin TY, Hung JN, Chiu YH, Tsai MH. Biomed Pharmacother 155 113766 (2022)
  274. Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. Resch MD, Wen K, Mazboudi R, Mulhall Maasz H, Persaud M, Garvey K, Gallardo L, Gottlieb P, Alimova A, Khayat R, Morales J, Bielefeldt-Ohmann H, Bowen RA, Galarza JM. Vaccines (Basel) 10 1997 (2022)
  275. Lack of Difference in Tocilizumab Efficacy in the Treatment of Severe COVID-19 Caused by Different SARS-CoV-2 Variants. Oliynyk O, Barg W, Oliynyk Y, Dubrov S, Gurianov V, Rorat M. J Pers Med 12 1103 (2022)
  276. Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. Sariol CA, Serrano-Collazo C, Ortiz EJ, Pantoja P, Cruz L, Arana T, Atehortua D, Pabon-Carrero C, Espino AM. Viruses 13 2405 (2021)
  277. Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. Kodchakorn K, Kongtawelert P. PLoS One 17 e0277745 (2022)
  278. PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. Hung JN, Kha Vo DN, Thanh Ho HP, Tsai MH. Biomacromolecules 23 3535-3548 (2022)
  279. Simultaneous measurement of the antibody responses against SARS-CoV-2 and its multiple variants by a phage display mediated immuno-multiplex quantitative PCR-based assay. Chen H, Li S, Wang J, He S, Wang D, Qian Z, Hu D, Qi F, Hu K, Luo C, Wang J. Front Microbiol 13 968036 (2022)
  280. Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: A mathematical modeling study. Lin YF, Li Y, Duan Q, Lei H, Tian D, Xiao S, Jiang Y, Sun C, Du X, Shu Y, Zou H. J Med Virol 94 3722-3730 (2022)
  281. Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. Caucci S, Corvaro B, Tiano SML, Valenza A, Longo R, Marinelli K, Ferreri ML, Spiridigliozzi P, Salvoni G, Bagnarelli P, Menzo S. Vaccines (Basel) 9 1124 (2021)
  282. A fractal scaling analysis of the SARS-CoV-2 genome sequence. Meraz M, Vernon-Carter EJ, Rodriguez E, Alvarez-Ramirez J. Biomed Signal Process Control 73 103433 (2022)
  283. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern. Xu J, Zhang Y, Qu P, Shamseldin MM, Yoo SJ, Misny J, Thongpan I, Kc M, Hall JM, Evans JP, Eltobgy M, Lu M, Ye C, Chamblee M, Liang X, Martinez-Sobrido L, Amer AO, Yount JS, Boyaka PN, Peeples ME, Liu SL, Dubey P, Li J. Proc Natl Acad Sci U S A 120 e2220403120 (2023)
  284. A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants. Liu Y, Zhao D, Wang Y, Chen Z, Yang L, Li W, Gong Y, Gan C, Tang J, Zhang T, Tang D, Dong X, Yang Q, Valencia CA, Dai L, Qi S, Dong B, Chow HY, Li Y. Front Immunol 13 1011484 (2022)
  285. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks. Alfaleh MA, Alsulaiman RM, Almahboub SA, Nezamuldeen L, Zawawi A, Aljehani ND, Yasir M, Abdulal RH, Alkhaldi R, Helal A, Alamri SS, Malki J, Alhabbab RY, Abujamel TS, Alhakamy NA, Alnami A, Algaissi A, Hassanain M, Hashem AM. Antib Ther 7 53-66 (2024)
  286. Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains. Zhang Y, Wang R, He C, Zhang YF, Luo Z, Luo J, Chen S, Jin Y, Xie B, Liu Y. Nano Today 43 101393 (2022)
  287. Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. Xu X, Hong Y, Chen E, Wang Y, Ma B, Li J, Su W, Zhou Y, Zhang M. Vaccines (Basel) 10 2110 (2022)
  288. Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study. Glebov OO, Mueller C, Stewart R, Aarsland D, Perera G. BMC Med 21 209 (2023)
  289. Delta SARS-CoV-2 s2m Structure, Dynamics, and Entropy: Consequences of the G15U Mutation. Makowski JA, Kensinger AH, Cunningham CL, Frye CJ, Shine M, Lackey PE, Mihailescu MR, Evanseck JD. ACS Phys Chem Au 3 434-443 (2023)
  290. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2. Lázaro-Gorines R, Pérez P, Heras-Murillo I, Adán-Barrientos I, Albericio G, Astorgano D, Flores S, Luczkowiak J, Labiod N, Harwood SL, Segura-Tudela A, Rubio-Pérez L, Nugraha Y, Shang X, Li Y, Alfonso C, Adipietro KA, Abeyawardhane DL, Navarro R, Compte M, Yu W, MacKerell AD, Sanz L, Weber DJ, Blanco FJ, Esteban M, Pozharski E, Godoy-Ruiz R, Muñoz IG, Delgado R, Sancho D, García-Arriaza J, Álvarez-Vallina L. Adv Sci (Weinh) 10 e2304818 (2023)
  291. Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals. Tan CW, Zhu F, Chia WN, Young BE, Yeoh AYY, Althaus T, Yung CF, Yap WC, Lim BL, Chen MI, Zhang J, Mah YY, Voiglio E, Sigal A, Huo J, Xu S, Tan YJ, Lam KP, Lye D, Wang LF. Hlife 1 26-34 (2023)
  292. Early Emergence Phase of SARS-CoV-2 Delta Variant in Florida, US. Cella E, Ali S, Schmedes SE, Rife Magalis B, Marini S, Salemi M, Blanton J, Azarian T. Viruses 14 766 (2022)
  293. Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron. Ison MG, Popejoy M, Evgeniev N, Tzekova M, Mahoney K, Betancourt N, Li Y, Gupta D, Narayan K, Hershberger E, Connolly LE, Yalcin I, Das AF, Genge J, Smith M, Campanaro E, Hawn P, Schmidt P, STAMP Study Group . Open Forum Infect Dis 10 ofad279 (2023)
  294. Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo. Wang Q, Peng L, Nie Y, Shu Y, Zhang H, Song Z, Li Y, Hu H, Li L, Wang X, Liu J, Li J, Shi Z, Deng F, Guo Y, Zhou Y, Yan B, Hu Z, Wang M. Virol Sin 38 257-267 (2023)
  295. Induction of Superior Systemic and Mucosal Protective Immunity to SARS-CoV-2 by Nasal Administration of a VSV-ΔG-Spike Vaccine. Yahalom-Ronen Y, Melamed S, Politi B, Erez N, Tamir H, Bar-On L, Ryvkin J, Leshkowitz D, Israeli O, Weiss S, Ben-Shmuel A, Barlev-Gross M, Cherry Mimran L, Achdout H, Paran N, Israely T. Vaccines (Basel) 12 491 (2024)
  296. Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic. Choe PG, Kim Y, Chang E, Kang CK, Kim NJ, Cho NH, Park WB, Oh MD. J Korean Med Sci 37 e67 (2022)
  297. Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition. Hong H, Noh JY, Lee H, Choi S, Choi B, Kim JK, Shin EC. Immune Netw 22 e23 (2022)
  298. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Brunner-Ziegler S, Spath T, Kornek G, König F, Parschalk B, Schnetzinger M, Straßl RP, Savic R, Foit A, Resch H, Thalhammer F. Clin Microbiol Infect 28 596-601 (2022)
  299. Psychological research of the children with chronic kidney disease and their guardians during the COVID-19 pandemic. Xiong HY, Zhang G, Wang L, Li Z, Shen Q, Li Y, Zhu H, Du Y, Sun L, Zhao B, Zhao L, Fu H, Li X, Gao X, Hao S, Ding J, Chen Z, Xu Z, Liu X, Tao Y, Zhang A, Li Q, Wang M. Front Public Health 10 922678 (2022)
  300. RT-PCR/MALDI-TOF Diagnostic Target Performance Reflects Circulating SARS-CoV-2 Variant Diversity in New York City. Hernandez MM, Banu R, Gonzalez-Reiche AS, Gray B, Shrestha P, Cao L, Chen F, Shi H, Hanna A, Ramírez JD, van de Guchte A, Sebra R, Gitman MR, Nowak MD, Cordon-Cardo C, Schutzbank TE, Simon V, van Bakel H, Sordillo EM, Paniz-Mondolfi AE, Mount Sinai PSP Study Group. J Mol Diagn 24 738-749 (2022)
  301. SARS-CoV-2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity. Golcuk M, Hacisuleyman A, Yilmaz SZ, Taka E, Yildiz A, Gur M. J Chem Inf Model 62 2490-2498 (2022)
  302. SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. Di Y, Lew J, Goncin U, Radomska A, Rout SS, Gray BET, Machtaler S, Falzarano D, Lavender KJ. Viruses 14 2272 (2022)
  303. Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults. Schmidt P, Gong J, Narayan K, Gupta D, Engler F, Li Y, Copans A, Campanaro E. Infect Dis Ther 12 1365-1377 (2023)
  304. Sera of patients infected by earlier lineages of SARS-CoV-2 are capable to neutralize later emerged variants of concern. Pauvolid-Corrêa A, Caetano BC, Machado AB, Ferreira MA, Valente N, Neves TK, Geraldo K, Motta F, Dos Santos VGV, Grinsztejn B, Siqueira MM, Resende PC. Biol Methods Protoc 7 bpac021 (2022)
  305. The increase in SARS-CoV-2 lineages during 2020-2022 in a state in the Brazilian Northeast is associated with a number of cases. Freitas MTS, Sena LOC, Fukutani KF, Dos Santos CA, Neto FDCB, Ribeiro JS, Dos Reis ES, Balbino VQ, de Sá Paiva Leitão S, de Aragão Batista MV, Lipscomb MW, de Moura TR. Front Public Health 11 1222152 (2023)
  306. VSV-ΔG-Spike Candidate Vaccine Induces Protective Immunity and Protects K18-hACE2 Mice against SARS-CoV-2 Variants. Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Achdout H, Erez N, Israeli O, Cohen-Gihon I, Chery Mimran L, Barlev-Gross M, Mandelboim M, Orr I, Feldmesser E, Weiss S, Beth-Din A, Paran N, Israely T. Viruses 15 1364 (2023)
  307. A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. Capoferri AA, Shao W, Spindler J, Coffin JM, Rausch JW, Kearney MF. Viruses 14 104 (2022)
  308. A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. Wang Z, Tang Q, Liu B, Zhang W, Chen Y, Ji N, Peng Y, Yang X, Cui D, Kong W, Tang X, Yang T, Zhang M, Chang X, Zhu J, Huang M, Feng Z. J Biomed Res 37 166-178 (2022)
  309. Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. Kandala B, Plock N, Chawla A, Largajolli A, Robey S, Watson K, Thatavarti R, Dubey SA, Cheung SYA, de Greef R, Stone J, Sachs JR. EBioMedicine 84 104264 (2022)
  310. Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2. Rezaei A, Nazarian S, Samiei Abianeh H, Kordbacheh E, Alizadeh Z, Mousavi Gargari SL. Avicenna J Med Biotechnol 14 270-277 (2022)
  311. Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. Zhu Y, Lu Y, Zhou C, Tong G, Gao M, Zhan Y, Wang Y, Liang R, Li Y, Gao T, Wang L, Zhang M, Cheng J, Gong J, Wang J, Zhang W, Qi J, Cui M, Zhu L, Xiao F, Zhu L, Xu Y, Zheng Z, Zhou Z, Cheng Z, Hong P. Med 3 568-578.e3 (2022)
  312. Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain. Patrick C, Upadhyay V, Lucas A, Mallela KMG. J Mol Biol 434 167622 (2022)
  313. COVID-19: Impact on linguistic and genetic isolates of India. Singh PP, Suravajhala P, Basu Mallick C, Tamang R, Rai AK, Machha P, Singh R, Pathak A, Mishra VN, Shrivastava P, Singh KK, Thangaraj K, Chaubey G. Genes Immun 23 47-50 (2022)
  314. Clinical Characteristics of COVID-19 Patients' Postvaccination. Zhang XB, Yang SJ, Lin Y, Chen LL, Zhuang YL, Zeng HQ. Viral Immunol 35 236-243 (2022)
  315. Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. Vicenti I, Basso M, Dragoni F, Gatti F, Scaggiante R, Fiaschi L, Parisi SG, Zazzi M. Vaccines (Basel) 10 580 (2022)
  316. Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein. Tarek Ibrahim M, Tao P. J Biomol Struct Dyn 41 7144-7157 (2023)
  317. Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening. O'Reilly S, Kenny G, Alrawahneh T, Francois N, Gu L, Angeliadis M, de Masson d'Autume V, Garcia Leon A, Feeney ER, Yousif O, Cotter A, de Barra E, Horgan M, Mallon PWG, Gautier V. PLoS One 18 e0294262 (2023)
  318. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection. Liu C, Das R, Dijokaite-Guraliuc A, Zhou D, Mentzer AJ, Supasa P, Selvaraj M, Duyvesteyn HME, Ritter TG, Temperton N, Klenerman P, Dunachie SJ, Paterson NG, Williams MA, Hall DR, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Nat Commun 15 3284 (2024)
  319. Epidemiological analysis of the emergence and disappearance of the SARS-CoV-2 Kappa variant within a region of British Columbia, Canada. Ghafari C, Benusic M, Prystajecky N, Sbihi H, Kamelian K, Hoang L. Can Commun Dis Rep 48 22-26 (2022)
  320. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study. Qin K, Honjo K, Sherrill-Mix S, Liu W, Stoltz RM, Oman AK, Hall LA, Li R, Sterrett S, Frederick ER, Lancaster JR, Narkhede M, Mehta A, Ogunsile FJ, Patel RB, Ketas TJ, Cruz Portillo VM, Cupo A, Larimer BM, Bansal A, Goepfert PA, Hahn BH, Davis RS. PLoS Med 20 e1004157 (2023)
  321. Higher correlation between neutralizing antibodies and surrogate neutralizing or binding antibodies in COVID-19 patients than vaccine recipients. Lerdsamran H, Anusorntanawat R, Sangsiriwut K, Sawadpongpan S, Prasertsopon J, Thinpan N, Intalapaporn P, Techasuwanna R, Okada P, Puthavathana P. PLoS One 19 e0298033 (2024)
  322. Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. Dai YC, Lin YC, Ching LL, Tseng AC, Qin Y, Nerurkar VR, Wang WK. Front Med (Lausanne) 9 1019490 (2022)
  323. Impact of E484Q and L452R Mutations on Structure and Binding Behavior of SARS-CoV-2 B.1.617.1 Using Deep Learning AlphaFold2, Molecular Docking and Dynamics Simulation. Jiao Y, Xing Y, Sun Y. Int J Mol Sci 24 11564 (2023)
  324. Case Reports Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. Isnaini N, Mardian Y, Lokida D, Budiono F, Butar-Butar DP, Arlinda D, Salim G, Kosasih H, Wulan WN, Perodin J, Neal A, Lane HC, Karyana M. Front Med (Lausanne) 9 906469 (2022)
  325. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. Li J, Li X, Wang E, Yang J, Li J, Huang C, Zhang Y, Chen K. Vaccines (Basel) 10 2111 (2022)
  326. Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study. Liao X, Li D, Liu J, Liu Z, Ma Z, Dong J, Yang X, Shu D, Yuan J, Liu L, Zhang Z. Virol J 19 218 (2022)
  327. Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants. Du W, Jiang P, Li Q, Wen H, Zheng M, Zhang J, Guo Y, Yang J, Feng W, Ye S, Kamara S, Jiang P, Chen J, Li W, Zhu S, Zhang L. Microbiol Spectr 11 e0356222 (2023)
  328. PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application. Zhang Z, Zhou J, Ni P, Hu B, Jolicoeur N, Deng S, Xiao Q, He Q, Li G, Xia Y, Liu M, Wang C, Fang Z, Xia N, Zhang ZR, Zhang B, Cai K, Xu Y, Liu B. NPJ Vaccines 8 38 (2023)
  329. Polymerized porin as a novel delivery platform for coronavirus vaccine. Yang Z, Hua L, Yang M, Li W, Ren Z, Zheng X, Chen H, Long Q, Bai H, Huang W, Ma Y. J Nanobiotechnology 20 260 (2022)
  330. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19. Zumbrun EE, Kaku CI, Dillinger L, Zak SE, Kuehne AI, Bakken RR, Koehler JW, Delp KL, Stefan CP, Kumar R, Kugelman JR, Moreau AM, Zeng X, Dye JM, Herbert AS, Narayan K, Walker LM. Antimicrob Agents Chemother 67 e0135322 (2023)
  331. Quantitative Reverse Transcription PCR Surveillance of SARS-CoV-2 Variants of Concern in Wastewater of Two Counties in Texas, United States. Langan LM, O'Brien M, Lovin LM, Scarlett KR, Davis H, Henke AN, Seidel SE, Archer N, Lawrence E, Norman RS, Bojes HK, Brooks BW. ACS ES T Water 2 2211-2224 (2022)
  332. Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2. Yu P, Ran J, Yang R, Zhu H, Lu S, Wu Y, Zhao T, Xiong T. Front Immunol 15 1374913 (2024)
  333. Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies. Kang H, Kim D, Min K, Park M, Kim SH, Sohn EJ, Choi BH, Hwang I. Clin Exp Vaccine Res 11 285-289 (2022)
  334. SARS-CoV-2 molecular epidemiology in Slovenia, January to September 2021. Janezic S, Mahnic A, Kuhar U, Kovač J, Jenko Bizjan B, Koritnik T, Tesovnik T, Šket R, Krapež U, Slavec B, Malovrh T, Battelino T, Rupnik M, Zohar Cretnik T, NLZOH COVID-19 team, CISLD NGS team, Members of the NLZOH COVID-19 team Members of the CISLD NGS team, UMC Ljubljana. Euro Surveill 28 (2023)
  335. SARS-CoV-2 omicron BA.1.1 is highly resistant to antibody neutralization of convalescent serum from the origin strain. Li J, Li X, Mao H, Huang C, Sun Y, Miao L, Li J, Song W, Zhang Y, Huang J, Chen K. Virus Res 332 199131 (2023)
  336. SARS-CoV-2 variant surge and vaccine breakthrough infection: A computational analysis. Khater I, Nassar A. Inform Med Unlocked 29 100873 (2022)
  337. Spike protein mutations and structural insights of pangolin lineage B.1.1.25 with implications for viral pathogenicity and ACE2 binding affinity. Akter S, Oliveira JIN, Barton C, Sarkar MH, Shahab M, Banu TA, Goswami B, Osman E, Uzzaman MS, Nafisa T, Molla MA, Yeasmin M, Farzana M, Habib A, Shaikh AA, Khan S. Sci Rep 13 13146 (2023)
  338. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses. Zhang L, Chen H, Yang S, Zhao Y, Shen X, He X, Ye H, Wang D, Lou J, Wang Y, Wu S. Front Immunol 13 990071 (2022)
  339. The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials. Murphy RL, Paramithiotis E, Sugden S, Chermak T, Lambert B, Montamat-Sicotte D, Mattison J, Steinhubl S. Front Immunol 13 923106 (2022)
  340. Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1. Han H, Luo RH, Long XY, Wang LQ, Zhu Q, Tang XY, Zhu R, Ma YC, Zheng YT, Zou CG. Elife 13 e85985 (2024)
  341. A unique cytotoxic CD4+ T cell-signature defines critical COVID-19. Baird S, Ashley CL, Marsh-Wakefield F, Alca S, Ashhurst TM, Ferguson AL, Lukeman H, Counoupas C, Post JJ, Konecny P, Bartlett A, Martinello M, Bull RA, Lloyd A, Grey A, Hutchings O, Palendira U, Britton WJ, Steain M, Triccas JA. Clin Transl Immunology 12 e1463 (2023)
  342. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19. Holdenrieder S, Dos Santos Ferreira CE, Izopet J, Theel ES, Wieser A. Front Public Health 11 1290402 (2023)
  343. Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines. Vinzón SE, Lopez MV, Cafferata EGA, Soto AS, Berguer PM, Vazquez L, Nusblat L, Pontoriero AV, Belotti EM, Salvetti NR, Viale DL, Vilardo AE, Avaro MM, Benedetti E, Russo ML, Dattero ME, Carobene M, Sánchez-Lamas M, Afonso J, Heitrich M, Cristófalo AE, Otero LH, Baumeister EG, Ortega HH, Edelstein A, Podhajcer OL. NPJ Vaccines 8 149 (2023)
  344. Declining neutralizing antibody levels after SARS-CoV-2 mRNA vaccination: observational data from community point-of-care testing service in Brno, Czechia. Mravčík V, Kumpanová Valachovičová S, Vobořil J. Cent Eur J Public Health 30 111-118 (2022)
  345. Development of a single-chain variable antibody fragment against a conserved region of the SARS-CoV-2 spike protein. Gao T, Irie A, Kouwaki T, Oshiumi H. Sci Rep 14 14419 (2024)
  346. Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins. Kumar S, Dasgupta S, Sajadi MM, Snyder GA, DeVico AL, Ray K. Viruses 16 407 (2024)
  347. Dynamic characteristics of COVID-19 infection in Chinese children. Zhang Y, Li H, Xiang B, Du J, Huang Y, Lin G, Wu D. Am J Transl Res 14 6375-6381 (2022)
  348. Dynamic clade transitions and the influence of vaccination on the spatiotemporal circulation of SARS-CoV-2 variants. Banho CA, de Carvalho Marques B, Sacchetto L, Lima AKS, Parra MCP, Lima ARJ, Ribeiro G, Martins AJ, Barros CRDS, Elias MC, Sampaio SC, Slavov SN, Rodrigues ES, Santos EV, Covas DT, Kashima S, Brassaloti RA, Petry B, Clemente LG, Coutinho LL, Assato PA, da Silva da Costa FA, Grotto RMT, Poleti MD, Lesbon JCC, Mattos EC, Fukumasu H, Giovanetti M, Alcantara LCJ, Souza-Neto JA, Rahal P, Araújo JP, Spilki FR, Althouse BM, Vasilakis N, Nogueira ML. NPJ Vaccines 9 145 (2024)
  349. Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients. Zhou Z, Li D, Zhao Z, Shi S, Wu J, Li J, Zhang J, Gui K, Zhang Y, Ouyang Q, Mei H, Hu Y, Li F. PLoS Comput Biol 19 e1011383 (2023)
  350. Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination. Yin Z, Chen JL, Lu Y, Wang B, Wang B, Godfrey L, Mentzer AJ, Yao X, Liu G, Wellington D, Zhao Y, Wing PAC, Dejnirattisa W, Supasa P, Liu C, Hublitz P, Beveridge R, Waugh C, Clark SA, Clark K, Sopp P, Rostron T, Mongkolsapaya J, Screaton GR, Ogg G, Ewer K, Pollard AJ, Gilbert S, Knight JC, Lambe T, Smith GL, Dong T, Peng Y. Cell Rep 42 112470 (2023)
  351. Evaluation of an identification method for the SARS-CoV-2 Delta variant based on the amplification-refractory mutation system. Zhang Q, Qiao R, Niu J, Xiong X, Wang N, Zhang R, Luo S, Guo Y, Liu Z, Peng L, Zhang S, Tan G, Song K, Sun M, Xu L, Zhang R, Wu X. Front Cell Infect Microbiol 13 1180297 (2023)
  352. Gold Nanoparticle Virus-like Particles Presenting SARS-CoV-2 Spike Protein: Synthesis, Biophysical Properties and Immunogenicity in BALB/c Mice. Salazar VA, Comenge J, Suárez-López R, Burger JA, Sanders RW, Bastús NG, Jaime C, Joseph-Munne J, Puntes V. Vaccines (Basel) 12 829 (2024)
  353. High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell. Yang Y, Liu S, Luo Y, Wang B, Wang J, Li J, Li J, Ye B, Wang Y, Xi JJ. PLoS Pathog 19 e1011119 (2023)
  354. Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China. Li L, Zhang J, Sun R, Liu H, Cheng G, Fan F, Wang C, Li A, Liang H, Yu Z, Wang G, Ren Z. BMC Public Health 24 556 (2024)
  355. Incidence and outcome of SARS-CoV-2 reinfection in the pre-Omicron era: A global systematic review and meta-analysis. Ismail NF, Rahman AE, Kulkarni D, Zhu F, Wang X, Del Carmen Morales G, Srivastava A, Allen KE, Spinardi J, Kyaw MH, Nair H. J Glob Health 13 06051 (2023)
  356. Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals. Park JS, Jeon J, Um J, Choi YY, Kim MK, Lee KS, Sung HK, Jang HC, Chin B, Kim CK, Oh MD, Lee CS. Infect Chemother 56 25-36 (2024)
  357. Molecular characterization, phylogenetic and variation analyses of SARS-CoV-2 strains in India. Banerjee M, Chakraborty D, Chakraborty A. Virusdisease 35 462-477 (2024)
  358. Letter Neutralization of B.1.617.2 variant through antibodies elicited by ChAdOx1-S, BBIBP-CorV, and Gam-COVID-Vac in an Argentinean cohort. Blanco S, Aguilar JJ, Spinsanti L, Diaz A, Beranek M, Rivarola ME, Fernández E, Mangeaud A, Konigheim BS, Gallego SV. J Med Virol 95 e28286 (2023)
  359. Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population. Hernández-Bello J, Lorenzo-Leal AC, Muñoz-Valle JF, Morales-Núñez JJ, Díaz-Pérez SA, Hernández-Gutiérrez R, Bach H. PLoS One 19 e0299520 (2024)
  360. Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE). Ison MG, Weinstein DF, Dobryanska M, Holmes A, Phelan AM, Li Y, Gupta D, Narayan K, Tosh K, Hershberger E, Connolly LE, Yalcin I, Campanaro E, Hawn P, Schmidt P, EVADE Study Group. Open Forum Infect Dis 10 ofad314 (2023)
  361. Progressive Evolutionary Dynamics of Gene-Specific ω Led to the Emergence of Novel SARS-CoV-2 Strains Having Super-Infectivity and Virulence with Vaccine Neutralization. Maiti AK. Int J Mol Sci 25 6306 (2024)
  362. Raman Fingerprints of SARS-CoV-2 Omicron Subvariants: Molecular Roots of Virological Characteristics and Evolutionary Directions. Pezzotti G, Ohgitani E, Fujita Y, Imamura H, Pappone F, Grillo A, Nakashio M, Shin-Ya M, Adachi T, Yamamoto T, Kanamura N, Marin E, Zhu W, Inaba T, Tanino Y, Nukui Y, Higasa K, Yasukochi Y, Okuma K, Mazda O. ACS Infect Dis 9 2226-2251 (2023)
  363. Real-world effectiveness of mRNA COVID-19 vaccines in the elderly during the Delta and Omicron variants: Systematic review. Palalay H, Vyas R, Tafuto B. World J Metaanal 11 167-180 (2023)
  364. Recursive state and parameter estimation of COVID-19 circulating variants dynamics. Silva DM, Secchi AR. Sci Rep 12 15879 (2022)
  365. SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia. Ghiffari A, Anwar C, Hasyim H, Iskandar I, Kamaluddin MT. Acta Biomed 93 e2022018 (2022)
  366. The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice. Yang J, Fan H, Yang A, Wang W, Wan X, Lin F, Yang D, Wu J, Wang K, Li W, Cai Q, You L, Pang D, Lu J, Guo C, Shi J, Sun Y, Li X, Duan K, Shen S, Meng S, Guo J, Wang Z. Vaccines (Basel) 12 742 (2024)
  367. The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86. Zhou D, Supasa P, Liu C, Dijokaite-Guraliuc A, Duyvesteyn HME, Selvaraj M, Mentzer AJ, Das R, Dejnirattisai W, Temperton N, Klenerman P, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Nat Commun 15 2734 (2024)
  368. The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies. Shafaati M, Bagherzadeh K, Lotfinia M, Karimi H, Teimoori A, Razazian M, Meidaninikjeh S, Hosseini H, Jamshidi HR, Jalili H, Abdoli A. Heliyon 9 e14108 (2023)
  369. Editorial Vaccination and Future of Coronavirus. Moghadami M, Amini M, Moghadami M. Iran J Med Sci 47 391-393 (2022)
  370. Whole-Genome Sequences Analysis Displays Relationship of SARS-CoV-2 Delta Variant Between Four Local Cases and Passengers of a Flight from South Africa - Shenzhen City, Guangdong Province, China, June 2021. He Y, Zhang R, Lyu Q, Peng B, Mei S, Sun Y, Kong D, Peng C, Lyu Z, Wei X, Zhu C, Xiao X, Li S, Lu Q, Chen J, Zhang H, Zou X, Feng T, Chen L. China CDC Wkly 3 1075-1078 (2021)


Quick links